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Abstract 
Targeting of human tissues by nanomedicines can occur both passively, benefiting from 
the enhanced permeation and retention (EPR) effect, and actively, through design elements 
which exploit the unique microenvironment (pH, redox environment, enzymatic expression 
etc...) of specific tissues.  In this study novel drug delivery systems (DDS) are designed to 
exploit the enzymatic and pH environments of human tissues. Specifically, the enzymes matrix 
metalloproteinase (MMP) 2 and 9 are known to be associated strongly with aggressively invasive 
cancer and are expressed in very high levels in tumour tissues. These highly studied enzymes 
have been shown to selectively cleave the peptide sequence PVGLIG. In addition, the pH in 
different organs and cells in the human body can vary significantly creating opportunity to 
trigger pH-sensitive systems.  
The peptide PVGLIG, which is known to be selectively cleaved by the tumor-associated 
enzyme matrix metalloproteinase-2 (MMP-2), was conjugated to α-alkene poly(trimethylene 
carbonate) (PTMC) blocks of varying sizes via UV-initiated thiol-ene “click” chemistry. The 
PTMC precursor was synthesized by metal-free ring-opening polymerization using allyl alcohol 
as an initiator and an N-heterocyclic carbene as an organic catalyst. The unprecedented 
PVGLIG-b-PTMCn hybrids were self-assembled in aqueous solution and various sub-micron 
sized morphologies obtained by a nanoprecipitation process. Characterization of particle 
morphology was carried out by multi-angle dynamic light scattering (DLS) and static light 
scattering (SLS) evidencing spherical nanoparticles with different morphologies and narrow size 
distributions. Microstructure details were also observed on transmission electron micrographs 
and were in good agreement with light scattering measurements showing the assembly of core-
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shell, large compound micelles and vesicle morphologies, the particle morphology varying with 
the hydrophilic weight fractions (ƒ) of the hybrids. These nanostructures displayed selective 
degradation in the presence of the cancer-associated enzyme MMP-2, as probed by the 
morphological change both by TEM and DLS. All these results demonstrated that PVGLIG-b-
PTMC  hybrids were suitable to target the tumor microenvironment. 
The synthetic strategy developed for production of PTMCn-b-PVGLIG diblock systems 
was then expanded for the synthesis of multi-functional a triblock copolymer. The synthetic 
semi-crystalline polymer PTMC50 was conjugated to the synthetic poly(amino acid) 
poly(glutamic acid) (PGA) using the peptide PVGLIG as a linker by a combination of UV-
initiated thiol-ene coupling and ROP. Stable, monodispersed, sub-micron sized polymersomes 
were subsequently obtained by self-assembly and characterized by dynamic and static light 
scattering (DLS and SLS) and TEM.  These vesicles showed selective degradation in the 
presence of MMP-2 as probed by DLS. The model drug imipramine hydrochloride was loaded at 
35 % encapsulation efficiency by co-precipitation and displayed a controlled drug-behaviour.. 
Drug release rates from these vesicles showed several fold increases when exposed to pH, 
temperature and most significantly, the tumor-associated enzyme MMP-2. Such structures may 
hold promise as future specific and controlled drug-delivery systems. 
Control of membrane integrity is a key factor in producing stable particles for drug 
delivery. PTMC50-b-PVGLIG-b-PGA15 nano-vesicles were subjected to multiple rounds of 
heating and cooling in order to probe the effect of membrane melting on the structure and 
stability of the vesicles. Vesicles are observed to undergo a chain-melting transition resulting in 
significant size and morphology changes when heated above the melting temperature of the 
PTMC block for extended periods. This morphology change is linked to increases in the 
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structure melting temperature and molar melting enthalpy towards that of the bulk material. This 
increase is suggestive of a higher degree of crystallinity attained in larger vesicles.. 
Towards a better understanding of how the drug-carrier relationship impacts 
encapsulation and release, isothermal titration calorimetry (ITC) was used to probe the chemical 
interactions between two model drugs and a polymersome carrier. The amphiphilic copolymer 
PTMC30-b-PGA13 was synthesized using a chemical platform previously established based on a 
combination of organo-catalyzed ring-opening polymerization (ROP) and UV-initiated thiol-ene 
coupling. The copolymer was self-assembled using a nanoprecipitation technique to form stable 
polymersomes with low PDI. Procaine hydrochloride (PrHy) or imipramine hydrochloride (IMI) 
was loaded into the vesicles as model drugs by co-precipitation. The loading of these drugs and 
release from the vesicles was monitored used drug-selective electrodes at pH 7.4 and 4.5. The 
significant differences in the loading and release of the two drugs from the vesicle carrier 
correlates well with the drug-carrier interactions probed by ITC. High intensity interaction was 
clearly linked with a higher drug loading capacity and a slower drug release rate. The drug-
carrier interaction was monitored by ITC at pH 9.5, 7.4 and 4.5 and was in good agreement with 
the observed loading and release rates. 
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Chapter 1 Introduction 
 Hybrid materials based on conjugation between biocompatible polymers and biologically 
relevant peptide sequences have recently emerged as a new and exciting class of soft matter 
materials
1–3
. The recent developments in synthetic methods allowed the design of sophisticated 
hybrid materials which take advantage of the chemical, physical and stimuli-responsive 
properties of both polymers and peptides, in a significant step towards biomimetic materials. 
Through advances in our understanding of the self-assembly phenomenon, these hybrid materials 
can be assembled into a variety of architectures, incorporating biologically relevant peptide 
sequences as structural elements in nanoparticles
3–7
. Such hybrid materials can be engineered to 
address major challenges in targeted cancer therapy and drug delivery. The design of 
multifunctional drug-delivery systems, combining ability to load a large amount of therapeutic 
molecules, possibility to release its content in a spatial and temporal controlled manner, and 
serving as a contrast agent for magnetic resonance imaging or other imaging methods is the 
major challenge facing nanomedicine today
8–10
. 
 
The main challenge of the coming decade is to move from the current use of hybrid 
materials in a “passive” way to an “active” one, where the material itself will have a functional 
role, mimicking the activity of molecules and substrates in biological systems. In this context, 
our project aims at developing new nano-carriers for drug delivery applications based on 
biologically relevant peptides and biocompatible polymers. 
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Targeting of cancer tissue by nanomedicines can occur both passively, benefiting from 
the enhanced permeation and retention (EPR) effect, and actively, through design elements that 
exploit the unique microenvironment (pH, redox environment, enzymatic expression etc...) of 
tumour tissue. Active targeting relies on stimuli-responsive elements in the drug delivery system 
(DDS) to target unique characteristics of disease tissues. DDSs with responsive elements rely on 
these unique microenvironmental conditions to trigger and/or control drug release at the target 
site, either by enhancing the permeability of the DDS or by completely destabilizing the DDS. 
Active targeting can also include targeting by tissue-specific antibodies or receptor-specific 
ligands conjugated to the DDS. In this study a novel DDSs are designed to exploit the enzymatic 
environment of invasive tumour tissues. Specifically, the enzymes matrix metalloproteinase 
(MMP) 2 and 9 are known to be associated strongly with aggressively invasive cancer and are 
highly expressed in tumour tissues. These widely studied enzymes have been shown to 
selectively cleave the peptide sequence PVGLIG.  
 
  This project will focuses on the design of nanostructures from polymer-peptide hybrid 
materials. We seek to incorporate the biologically-relevant peptide PVGLIG into nanoparticles to 
act as a structural element. In this way structures can be disrupted in the presence of the tumor-
associated enzymes MMP-2 and 9. It is believed that this peptide would be able to act as a 
trigger for the structural degradation of drug-loaded nanoparticles when in contact with MMP-
2,9, resulting in an enhanced drug release. One of the primary goals of this project is to use the 
PVGLIG peptide as a linker between two larger polymer blocks for the self-assembly and 
eventual disruption of polymersomes. 
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 A primary component of the systems used in this study will be poly(trimethylene 
carbonate) (PTMC), a well-known semi-crystalline polymer. The crystallinity of PTMC has 
previously been shown to play a significant role in self-assembly, resulting in highly stable 
structures. The influence of this polymer in the development of polymer-peptide hybrids is 
addressed at length in this work. In addition, the poly(amino acid) poly(glutamic acid) PGA will 
be incorporated in order to give assembled nanostructures surface charge and pH-sensitivity. 
The project will also aim to modify traditional synthetic methods for the chosen polymers 
in order to synthesize them in less stringent conditions. The synthesis of the di and triblock 
systems is done using a combination of organocatalyzed ring-opening polymerization (ROP) and 
macromolecular thiol-ene click chemistry. Vesicles and other structures will be formed through a 
nanoprecipitation technique and drugs encapsulated during self-assembly.  Following synthesis 
and self-assembly, considerable effort will focus in the characterization of the produced 
nanostructures, with particular attention paid to understanding the relationship between particle 
morphology and copolymer characteristics.  
Within liposomes, and analogous polymersomes, membrane integrity and permeability 
can be largely influenced by the presence of crystallinity. Polymer and phospholipid chains are 
known to undergo a gel to liquid-crystal transition across the chain melting temperature (Tm), 
resulting in the occurrence of fusion and/or fission events and subsequent structural changes in 
the vesicles. These events are probed with the polymer-peptide hybrid vesicles assembled in this 
work by heating and cooling the structures across their Tm. This study aims to gain a better 
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understanding of the influence of the molecular subunits and crystallinity on vesicle membrane 
integrity and stability. 
In addition to the design and investigation of polymer-peptide hybrid materials for 
assembly of drug delivery systems, special attention will be given to understanding the 
relationship between drug-carrier interactions and their influence on drug loading and release. In 
simple systems drug release from a carrier occurs through simple diffusion across a membrane 
(acting as a physical barrier), however, in more complex systems other factors such as interaction 
forces, chemical affinity and membrane  permeability can play significant roles in the release 
rate. 
  This project is part of the International Doctoral School in Functional Materials and is a 
joint venture between the University of Bordeaux I and the University of Waterloo as well as an 
industrial partner; Vive Crop Protection Inc. 
Outline of Report 
This report is divided into 7 main chapters. Chapter 2 is a literature review on the 
subject of polymer vesicles. It broadly covers key structural characteristics of polymersomes as 
well as common self-assembly techniques. The literature review focuses largely on the use of 
polymersomes  in drug delivery applications, with special attention given to stimuli-responsive 
vesicles, hybrid materials and active targeting of polymersomes. This provides the broad 
knowledge base from which the current project was designed.  
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Chapter 3 focuses on the synthesis of diblock polymer-peptide hybrids and their 
subsequent self-assembly. The morphologies are characterized and discussed in detail in relation 
to the composition of the molecular subunits. The degradation of these structures in the presence 
of active enzymes is presented and the applications of these structures as drug delivery systems 
is discussed.  
Chapter 4 covers the synthesis of a triblock system in which an enzyme substrate is used 
as a linker between two polymer blocks. The assembly of vesicles is observed and drug loading 
and release studies are presented. Drug release under varying temperature, pH and in the 
presence of active enzymes is presented.  
The study outlined in Chapter 5 focuses on the effects of temperature and crystallinity 
on membrane integrity and the structure of hybrid vesicles. The observed changes in melting 
temperature, heat capacity and structure morphology are discussed at length with particular focus 
on vesicle fusion and fission events in relation to the chain-melting transition.  
The final research chapter of this report, Chapter 6, is an investigation of the effect of 
drug-carrier interaction on the loading and release of drugs from polymer vesicles. Two model 
drugs are investigated, and their interactions with polymer vesicles observed by isothermal 
titration calorimetry (ITC). The relevance of this work towards development of tailored drug-
carrier combinations is discussed.  
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 Chapter 7 outlines the relevant contributions of the work to the body of scientific 
knowledge. This chapter summarizes the conclusions of all research performed and the 
recommendations for continuation of this work. The next steps and potential applications of the 
major findings are presented.  
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Chapter 2 Literature Review 
Introduction to Polymer Vesicles 
Amphiphilic block copolymers are capable of self-assembly into a variety of 
nanostructure morphologies, with a broad range of applications
11–13
. Amphiphiles designed from 
di-block and tri-block copolymers as well as dendritic and graft copolymers have been used for 
nano-structure self assembly producing a broad range of particle morphology
3,14–16
. Structures as 
varied as micelles, lamellar, rod-like and a variety of unique architectures have been designed, 
exploiting a range of synthetic polymers. For application in biomedicine, however, 
polymersomes (or polymer vesicles) hold the greatest potential for development into clinically 
relevant drug delivery systems
17–19
. Key characteristics of polymer vesicles, such as long-
circulations times, stability and capacity to encapsulate both hydrophilic and hydrophobic 
payloads make these structures particularly appealing. Broadly speaking polymer vesicles are 
spherical particles analogous to liposomes with an aqueous internal cavity surrounded by a bi-
layer membrane with a hydrophobic interior
20
. However, compared to liposomes, polymer 
vesicles have significantly higher performance with thicker and more robust membranes, higher 
stability and longer circulation times
17,21,22
. The membrane is hydrophilic at both the interior and 
exterior surfaces acting as a physical barrier separating the aqueous core from the outside 
medium (Figure 1). Polymersomes have been assembled with sizes varying from < 100 nm to 
well above 1 µm. Due to the presence of both a hydrophilic compartment (aqueous cavity) and a 
hydrophobic compartment (membrane interior) polymer vesicle can be used for loading of a 
diverse range of payloads, including drugs, dyes and biologically relevant macromolecules
23–26
. 
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The possibility to load both hydrophilic and hydrophobic drugs into polymer vesicles is of 
particular interest for applications in drug delivery. 
 
Figure 1 Schematic illustration of a 3D cross-section of a polymer vesicle 
from a diblock system 
Polymer vesicles are generally comprised of a combination of synthetic block 
copolymers and/or poly(amino acid)s and can be developed to include biologically relevant 
macromolecules such as peptide or protein fragments
27–31
. The amphiphiles are comprised of one 
or more blocks covalently linked, in this manner, macrophase separation is avoided and self-
assembly on the nanoscale can occur
32
.  With particular applications in biomedicine, polymer 
vesicles have been shown to be highly stable in vitro as well as having long circulation times in 
vivo. The appeal of such polymer vesicles is the versatility with which they can be prepared due 
to the diversity of possible amphiphiles available. Variations in block composition and molecular 
weight can result in vesicles of different sizes and membrane permeability
32–34
. Additionally, 
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stimuli-responsive blocks, capable of rapid changes in microstructure in response to stimuli, 
incorporated into the vesicle structure can give the structures a wide range of sensitivities and 
properties
35–37
. Synthetic polymers may also be combined with additional blocks such as 
poly(amino acid)s or enzymatic substrates to further vary the vesicle responsiveness and 
characteristics
3,27
. Such materials can increase the interaction of nanostructures with a biological 
environment. The variety of synthetic techniques available for production of polymeric 
amphiphiles has allowed for the introductions of a range of functionalities or chemically and 
biologically active monomers. The stable and thick membranes (2-50 nm) of polymer vesicles 
have most often been achieved with amphiphiles of relatively high molecular weight, though 
smaller chain length polymers (< 20 repeating units) have more recently been exploited in such 
structures
38,39
. Biocompatibility and extended circulation times have been achieved by use of 
polymers with “stealth” properties such as poly(ethylene glycol) (PEG) and poly(oxazolines) 
(POZ). Additionally, such biocompatible, biodegradable and hydrophobic polymers have been 
used such as poly(trimethylene carbonate) (PTMC), poly(lactic acid) (PLA) and poly(Ɛ-
caprolactone) (PCL) 
3,40,41
.  Vesicles formed with PEG surface layers have been shown to have 
great “stealth” potential and have been exploited in a number of studies.   
In recent years polymer vesicles have gained special attention for their application as 
drug delivery systems (Figure 2)
17,41,42
. Their multi-compartment properties (hydrophilic cavity 
and hydrophobic core) for encapsulation of both hydrophilic and hydrophobic payloads makes 
them particularly attractive compared to other single-compartment structures such as micelles or 
nanogels. Additionally, their increased stability and circulation times have set them apart from 
analogues such as liposomes
43
. Research has largely focused on incorporation of stimuli-
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responsive materials into the structure of polymer vesicles in order to control in both a special 
and temporal fashion the release of drugs from the vesicles. Block copolymers that are 
responsive to pH
9,20,44
, temperature
45–47
, redox conditions
48,49
, light
50–52
, magnetic field
53,54
, ionic 
strength
49
 and concentration of glucose
55
 among other stimuli have been synthesized and used to 
prepare biodegradable and/or stimuli-responsive polymer vesicles. For applications as guided 
therapeutics and site-targeted payload delivery efforts have been made to enhance the 
nanostructure interaction with cellular features and biological sites.  This can be achieved by 
introducing targeting moieties, for example, antibodies, antibody fragments, or peptides and 
proteins on the surface of the polymer vesicles
56
. Polymer vesicles with these features can be 
directed to specific biological sites and can respond to local stimuli at a desired site. Targeted 
drug delivery systems have the potential to enhance therapeutic effects of drugs and reduce 
unwanted side-effects by minimizing damage to surrounding healthy tissues. Design of polymer 
vesicles requires an understanding of vesicle self-assembly, requirements for successful 
assembly as well as knowledge of characterization.  
11 
 
 
Figure 2 Schematic representation of vesicle self-assembly, payload 
encapsulation and release.
57
 
 
Additionally, research focus has shifted to design of biologically active vesicles that 
incorporate relevant peptide sequences as structural elements
3,4
. Such polymer-peptide hybrid 
structures are unique in that they have the potential to interact directly with cellular systems, 
either with enzymes in local environments or with cell receptors to encourage internalization
6
. 
Such hybrid vesicles represent the next step towards biomimetic nanostructures. 
Self-Assembly of Polymer Vesicles 
Generally speaking the structure of polymer vesicles is defined by a single bi-layer 
membrane enclosing an aqueous cavity, however it is worth noting that a broad range of other 
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vesicle conformations have been observed. Figure 3 shows representative microphraphs of more 
exotic vesicle morphologies that have been observed. This review will focus on the more 
traditional single bi-layer vesicles and the methods of preparation involved with those. 
 
Figure 3 Micrographs of the diversity of vesicle morphology observed. A) 
Small vesicles (PS410-b-PAA13), B) Large polydisperse vesicles (PS100-b-
PEO30), C) entrapped vesicles (PS200-b-PAA20), D) hallow concentric vesicles 
(PS132-b-PAA20), E) onions (PS260-b-P4VPDI70), F) Tube-walled vesicles 
(PS100-b-PEO30)
58
 
 
Polymer vesicles are prepared by self-assembly of amphiphilic block copolymers and can 
be achieved by a number of different techniques. Most commonly polymer vesicles are prepared 
by either solvent-displacement
56,58–60
 (which includes rapid nanoprecipitation), also known as 
phase-inversion, and film or polymer rehydration
58
. Techniques involving extrusion or 
microfluidics
61
 can also be used for narrowing of vesicle size distributions or for assembly of 
multi-layer vesicles. In both solvent-displacement and film hydration, self-assembly relies on 
hydration of either a dried or dissolved block copolymer into vesicle structure. In the case of 
solvent-displacement the block copolymers must first be well-dissolved in a solvent appropriate 
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for both hydrophilic and hydrophobic components of the amphiphile. The solution is then 
hydrated with aqueous solution. The hydration process renders the hydrophobic blocks of the 
amphiphile insoluble, triggering the self-assembly process. By varying the solvents used as well 
as the rate of hydration, the vesicle size and characteristics can be adjusted
61
. 
The second technique commonly used for vesicle assembly is film rehydration. This 
technique relies on hydration of a deposited copolymer film in order to induce the assembly of 
vesicles. As with solvent-displacement, polymers are first dissolved well in an organic phase 
appropriate for all blocks. A film is produced by deposition and evaporation of the organic 
phase. Finally, the film is rehydrated with an aqueous solution. The aqueous solution can 
permeate the polymer layer through defects, causing bulging and finally separation of the 
polymer from the surface and vesicle formation. Compared to solvent-displacement methods, 
film hydration produces vesicles with much larger size distributions. Distributions have been 
reduced by following the self-assembly by extrusion or by application of an electrical field 
during the self-assembly. The electrical current can help to control the rate of hydration of the 
polymer layer.  
By the processes described above amphiphilic block copolymers can assemble into a 
wide range of morphologies and are not limited to vesicles. Such morphologies include spherical 
or cylindrical micelles, core-shell or vesicles. The achieved morphology is dependent on a 
number of factors, including chemical properties of homopolymers, chain length and interaction 
forces, but is most closely correlated to the mass or volume ratio between the hydrophilic and 
hydrophobic components of the amphiphile.  Vesicle morphology is generally 
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thermodynamically favoured for copolymers with a hydrophilic weight fraction (f) between 10 – 
40 %. As the hydrophilic weight fraction is increased, traditionally, cylindrical micelles (45-
55%) or spherical micelles (55-70 %) are favoured
62,63
. The various morphologies achievable 
result in differing packing parameters (p) of the polymer chains; a numerical description of the 
chain stacking. Classically, for surfactants and surfactant-like polymers, the packing parameter is 
characterized by the hydrophobic-hydrophilic interface based on the mean curvature (H) and its 
Gaussian curvature (K). These parameters are related by the equations below, in which v is the 
volume of the hydrophobic part of the polymer, a is the interfacial area per molecule and l the 
chain length of the hydrophobic part of the polymer
64,65
. 
 
  
      
   
 
          
In addition to the hydrophilic weight fraction, varying particle morphologies can also be 
predicted by calculating the copolymer packing parameter. Different morphologies correspond to 
different values of p. In general, p < 1/3 results in a spherical morphology, 1/3 < p < 1/2 a 
cylindrical one and ½ < p < 1 is characteristic of a vesicle morphology
17
. All the scaling laws, 
some being purely empirical generally consider the system at thermodynamic equilibrium, in 
cases of fluid systems. Out of equilibrium conditions can also influence particle morphology and 
the formation of vesicles, particularly by altering the method and conditions of preparation, the 
materials used as well as experimental conditions such as solvent, polymer concentration and 
solvent-water volume ratio
64
.  
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Membrane Integrity and Crystallinity 
One of the key features of polymer vesicles is the enhanced stability of the membrane 
relative to liposomes. This stability has made these structures promising candidates for drug 
delivery vehicles. Within this context several attempts at varying the permeability and stability of 
vesicle membranes have been made. Modification of membrane stability has been demonstrated 
by Discher et al with a PEO-b-PBD and PGA-b-PBD vesicle system.
66
 The vesicles formed 
showed very high stability capable of hydration and dehydration without damage to the 
membrane. Stable, defect-free membranes were demonstrated with high micron-scale surface 
areas. The unique strength of the vesicle developed is attributed to the crystalline nature of the 
polymer blocks.  
Changes in membrane permeability are most commonly achieved by use of stimuli-
responsive materials. This strategy will be discussed further later in this review. Membrane 
permeability can also be enhanced by incorporation of biological structures and macromolecules 
into the vesicle membrane. This strategy is more analogous to the presence of intergral 
membrane proteins observed in biological systems. Biological membranes are significantly more 
complex than polymer or lipid vesicles produced in vitro, and are comprised of not only lipids, 
but also glycolipids, membrane proteins, small molecules and glycoproteins. With synthetic 
vesicles, incorporation of membrane proteins into the vesicle membrane has given rise to specific 
and reversible molecule exchange across the membrane. Such strategies have given rise to 
systems with enhanced permeability to fluid molecules, as well as delivery of DNA or exchange 
of ions for biomineralization.  
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In liposomal systems, membrane stability can be attributed in part to the ability for the 
saturated alkyl chains of phospholipids to crystallize within the membrane
14
. This crystallinity 
can give rise to a temperature-sensitivity due to the chain-transition temperature (also called the 
gel-liquid-crystal transition). Across this critical temperature, crystalline liposomes (and polymer 
vesicles) exhibit a change from a gel state to a liquid-crystal state, resulting in changes in the 
permeability of the membrane to diffusion
67
. This transition has been exploited in drug delivery 
systems as release kinetics are highest above the chain transition. By varying the molecular 
weights and composition of vesicle subunits this critical temperature can be tuned to give a 
temperature-sensitive membrane permeability
68
. 
 
Figure 4 Schematic representation of temperature induced morphology 
changes from PE-b-PEO copolymer. Temperature increases the hydrophobic 
character of the PE block inducing greater levels of self-assembly.
69
 
Although more common in liposomes, vesicles comprised of synthetic polymers have 
also been made using crystalline polymers
40,45,69–71
. Significant research has been done to exploit 
crystallinity in polymer structures to induce changes in membrane permeability and structure 
morphology. Most commonly, PEO has been used as a crystalline polymer in self-assembled 
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structures. Diblock copolymers comprised of PE-b-PEO have been shown to form compound 
micelles with crystalline character observed in the PEO cores within the structure
69
. The 
character of the crystalline regions in these structures differed significantly from that of the bulk 
material due to the confinement of the PEO chains within the structure. Specifically, a large 
change in the chain-transition temperature was observed. In this system heating above the chain-
transition temperature was shown to induce rearrangement of the crystalline regions and a 
morphology change in the structures. The observed progression from copolymer to structure is 
shown schematically in Figure 4. In other examples, semi-crystalline copolymers were shown to 
form lamellar structures, spherical micelles as well as cylindrical micelles
69
. Crystallization was 
evidenced to be the main driving force in the formation of these structures.  
Co-polymers for Nanostructure and Vesicle Formation 
The basic structural element of polymer vesicles is the amphiphilic block copolymer, 
comprised of one or more homopolymer blocks
17
. As such, the polymers chosen have a great 
influence on the final properties and therefore potential applications of the self assembled 
structures produced. The structural and chemical properties of polymer vesicles can be altered by 
using block copolymers of varying molecular weights, compositions, and structural 
characteristics.  For polymer vesicles and indeed all self-assembled structures, assembly relies on 
the presence of both a hydrophobic component and a hydrophilic component. The increased size 
of the amphiphiles relative to those of liposomes results in a lower membrane permeability. In 
addition the diversity of amphiphiles allows for greater functionalization a range of 
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characteristics of polymer vesicles. A broad range of both hydrophilic and hydrophobic polymers 
have been studied with success and will be discussed broadly.  
Some of the most common hydrophobic blocks used include such non-biodegradable 
polymers as poly(styrene) (PS), poly(butadiene) (PBD)
32,54,72,73
, poly(dimethylsiloxane) 
(PDMS)
74,75
 and poly(ethyl ethylene) (PEE)
32
. In the context of drug delivery systems often bio-
degradable systems are desired and hydrophobic block such as poly(lactide) (PLA)
46
, 
poly(caprolactone) (PCL)
56
 and poly(trimethylene carbonate) (PTMC)
3,40,56
 have been used due 
to their ability to undergo hydrolytic and/or enzymatic cleavage. Such cleavage can be controlled 
by varying the block molecular weight, pH and can be enhanced in the presence of specific 
enzymes. As with hydrophobic blocks, a broad range of hydrophilic polymers have been 
exploited in self-assembly. Most commonly, poly(acrylic acid) (PAA)
76,77
 and the poly(amino 
acid) poly(L-glutamic acid) (PGA)
54,73
 as well as poly(ethylene glycol) (PEG)
21,78,79
. 
Often, spatial and temporal control of drug release from delivery systems has relied on 
exploiting specific environmental conditions through the incorporation of stimuli-responsive 
materials into the vesicle structure
36,80
. With such materials, self-assembly can be achieved by 
simple alteration of environmental conditions. The most commonly used thermo-sensitive 
polymer is poly(N-isopropylacrylamide) (PNIPAAm) which has been extensively studied as a 
hydrophobic component in vesicle systems
46,81–83
. PNIPAAm is unique in that it has a sharp and 
tunable thermal transition within biologically relevant ranges (30 – 50 °C).  This lower critical 
solution temperature (LCST) is characterized by a phase transition of the polymer form coil to 
globule and from hydrophilic to hydrophobic
84,85
. This phase transition has allowed for the 
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assembly of nanostructures from PNIPAAm-containing conjugates by altering the environmental 
temperature. Polymer vesicles containing PNIPAAm were first reported by Feijen et al with the 
PEG-b-PNIPAAm system
86
. Subsequently, a number of other thermo-sensitive systems have 
been produced using PNIPAAm as well as other thermo-sensitive polymers.  
In addition to thermo-sensitive polymers, significant attention has been paid to pH-
responsive systems
20,87–89
. In general, such polymers are characterized by the presence of a 
titratable group which can be either protonated or deprotonated by changing of the 
environmental pH
90,91
. This protonation can result in changes in surface charge or cleavage and 
can be used to self-assemble vesicles or change the arrangement or morphology of nanoparticles. 
A prime example is the spontaneous assembly of vesicles from poly(2-
methacryloyloxyethylphosphorylcholine)-b-poly(2-(diisopropylamino) ethyl methacrylate) 
(PMPC-b-PDPA) observed upon undergoing a pH change from 2 to 6. The presence of tertiary 
amine groups on the PDPA group renders the system pH-sensitive. Deprotonation of the amine 
group renders the block insoluble and drives the self-assembly. 
Among pH-sensitive polymers, the poly(amino acid) PGA has been of particular interest, 
due to its biocompatible nature and success in forming highly stable structures. PBD-b-PGA
92
 
was shown to self-assemble at low pH conditions, once again, due to the titratable carboxyl 
pendant function. Vesicles showed a pH-tunable size between 100 and 150 nm. In this case the 
change in pH results in a coil-helix transition which drives the vesicle size change. This 
transition has been exploited with particularly impressive effect by Chécot et al by combining 
PGA with a second pH-sensitive poly(amino acid) poly(L-lysine) (PLys). Vesicles formed from 
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PLys-b-PGA have been termed “schizophrenic” due to their invertible membrane, as shown in 
Figure 5. At low pH PGA is hydrophobic and forms the membrane core, however as the pH is 
raised the membrane is inverted with the now hydrophobic PLys forming the membrane core.  
 
Figure 5 Self-assembly of “schizophrenic vesicles” from the di-block 
copolymer PLys-PGA. The hydrophobic and hydrophilic character of the 
two blocks are reversed by protonation and deprotonation of the copolymers 
with changes in pH.
92
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It is clear that there exists a great diversity of relevant stimuli-responsive materials 
that have been developed into nano-structured drug carriers. Table 1 below presents 
many of the recent systems that have been developed with particular emphasis on 
common copolymer systems and polymer-peptide hybrid materials. As well attention is 
given to systems with demonstrated sensitivities for control of degradation and/or 
payload release. 
Table 1 Polymer vesicles from polymer-peptide and polymer-poly(amino acid)s 
Polymer Formation Method Sensitivity/Target/Release 
Mechanism 
Reference 
PEG-b-PLA Solvent Displacement Enzymatic Degradation 93 
PEG-b-PCL Solvent Displacement Enzymatic Degradation 80 
PEG-b-PTMBPEC Solvent Displacement pH-triggered hydrolysis 20 
PBLG-b-HYA Solvent Displacement CD44 receptor 94 
PB-b-PGA Dissolution (Water) pH, Magnetic field, ionic 
strength 
73 
PTMC-b-PGA Solvent Displacement Magnetic field, pH 40 
PGA-b-PBD Hydration (High pH) pH (Size Change) 18 
PEG-b-(PG2MA-IND) Hydration (pH 2.0 – 3.5) pH (Hydrolysis) 90 
PEG-b-P2VP Solvent Displacement pH (deformation) 95 
PLys-b-PLE Solvent Displacement pH (deformation) 96 
PLLys-b-PLTyr Dissolution (Water) Lactobionolactone, cross-
linking 
97 
PLArg-b-PLLeu Solvent Displacement Cell-penetrating 97 
PMPC-b-PDPA Hydration (pH 2.0 – 6.0) pH < 6 98 
PEG-b-PS-b-PDEAMA Solvent Displacement pH (membrane 
permeability) 
99 
PLys-b-PGA Hydration (pH <4 or 
>10) 
pH (membrane inversion) 100 
PAMPA-b-PNIPAAm Dissolution, Heating Temperature 101 
PCEMA-b-PNIPAAm Dissolution, Heating Temperature 46 
PEG-b-PNIPAAm Dissolution, Heating Temperature 83 
PHA-b-PLLeu THF/Water processing Cell-penetrating 102 
mPEG-b-P(Asp) Dissolution (Tris-HCL, 
pH 7.4) 
PICsome 103 
PLGA-b-PPO-b-PLGA Dissolution (0.1 M KOH) pH and Temperature 104 
PLA-b-PNIPAAm Hydration Temperature 105 
22 
 
PEG-b-PPS-b-PEG Solvent Displacement Oxidation 55 
PEG-SS-PPS Film Rehydration Reduction 106 
PAA-b-PAzoMA Solvent Displacement UV light (deformation) 107 
PGA-b-PBD Fe203 in Water Magnetic field 
54 
PEG-b-PI Fe203, magnetic field Megnetic Field 
14 
PLL-b-PGly Film Rehydration pH 108 
PNIPAAm-b-PZLys Solvent Displacement pH and Temperature 109 
PBLG-b-K/E Hydration Enhanced immunogenicity 110 
 
The comprehensive summary given in table 1 provides an overview of current materials 
used in stimuli-responsive drug-delivery systems. Several of these systems will be described in 
detail in the sections to follow.  
Techniques for Characterization of Polymer Nanostructures 
A key component of the study of nanostructures in general (and vesicles in particular) is 
the ability to well-characterize and well-define the structure morphology. To this end, a number 
of techniques have been utilized, the most common of which are dynamic and static light 
scattering (DLS and SLS respectively). Light scattering techniques are used primarily for 
determination of size and polydispersity of dispersed nanostructures, providing both the 
hydrodynamic radius (RH) and the radius of gyration (RG)
111
. The comparison of these values 
gives the RG/RH ratio, a valuable indicator of structure morphology. Data produced from these 
measurements can also provide estimates of the mean molecular weight, aggregation number and 
the 2
nd
 viral coefficient (a measure of the chain-solvent interactions).  
 For dilute solutions, the scattered light measured from a polymer solution consists of the 
light scattered by the small solvent molecules plus the scattering from the large polymeric 
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species. If the scattering of the pure solvent is measured separately it can be subtracted from the 
solution scattering and the scattering due to the polymer molecules alone can be isolated. The 
data can be analyzed via a Zimm Plot in which the KC/Rθ values are plotted on the y-axis versus 
(sin (θ/2) + kc) on the x-axis, where k is an arbitrary constant.  
 Samples measured at constant concentration with varying angle of incident light can be 
extrapolated to a "zero-angle" point (with an x-coordinate equal to kc). Likewise, samples 
measured at constant angle with varying concentration can be extrapolated to a “zero-
concentration” point (with an x-coordinate equal to (sin2(θ/2)). Each of the extrapolated “zero 
angle” points can be extrapolated to zero-concentration (x value equal to 0). Similarly the 
extrapolated “zero-concentration” points can be extrapolated to zero-angle (x value equal to 0) 
and these two lines ideally intersect on the y-axis, the inverse of the molecular weight. The 
second viral coefficient is obtained from the initial slope of the zero-angle line and the radius of 
gyration is abstracted from the initial slope of the zero-concentration line.  
 A variation of the Zimm Plot used for analyzing high molecular weight samples. Was 
proposed by Berry, is to plot (KC/Rθ)
1 /2
 values. The intercept then yields the inverse of the 
molecular weight and the viral coefficient and radius of gyration can be determined similarly to 
the Zimm plot. The larger the difference in scattered intensity between the solvent and solution, 
the greater the precision of the parameters determined from the light scattering experiment. The 
increase in scattering intensity of the polymer solution over that of the pure solvent (at constant 
measuring angle) depends on four factors: the polymer molecular weight, the concentration of 
the polymer solution, the difference in the refractive index between the solvent and the polymer 
solution, and the wavelength of the laser. The polymer molecular weight is obviously fixed but 
the other parameters can be adjusted to increase the scattering intensity for a poor scattering 
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sample. Increasing the solution concentration (being careful to remain in the dilute solution 
region, changing the solvent to one with a larger dn/dc value for the particular polymer, and 
decreasing the wavelength of the laser, all increase the scattering intensity. 
Additionally, light scattering has been used to monitor vesicle stability under degradation 
conditions or under changing pH or temperature conditions. Zeta potential measurements by 
DLS can also give information about the electrophoretic mobility of nanostructures, depending 
on the surface charge of vesicles. This can be of particular interest for pH-sensitive structures. 
By measuring the light scattered from the particles, a number of properties can be extrapolated, 
however, for direct visualization of nanostructures, one must turn to microscopy. 
Microscopy provides direct visualization of nanoparticles for examination of size, 
morphology and uniformity. In general, optical microscopy is not suited for examination of nano 
vesicles due to its intrinsically limited resolution, and so electron microscopy is most commonly 
used. For high resolution images, both scanning and transmission electron microscopy (SEM and 
TEM) are used
62,63
 for visualization of nano-sized structures. In general, sample preparation can 
be quite simple, though depending on the polymers used, additional staining may be required. 
Sample preparation requires drying of the suspended vesicles onto a substrate, a process that can 
distort the structures. As a result, cryogenic-TEM is sometimes utilized. By this technique, 
vesicles are rapidly frozen in order to visualize more accurately
62
.  
With the aim of visualizing the specific localization of certain blocks within a vesicle 
structure, fluorophores can be used as labels and fluorescence microscopy used
112
. By this 
method, again limited by intrinsic resolution, specific regions of vesicle structures can be 
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accurately and clearly seen, giving information about their internal structure. Confocal laser 
scanning microscopy (CLSM) is another popular tool for visualization of polymer vesicles
113,114
. 
Optical slices of polymer vesicles in the z-direction can be obtained by using CLSM and in 
principle the slices can be combined providing a 3D stacked vesicular image. One of the 
interesting possibilities of fluorescence techniques is to study the dynamics such as diffusion and 
rotational mobility of nanostructures by time-resolved measurements.  
Nanostructures from Polymer-Peptide Hybrids 
 In recent years, research has moved past the use of simple synthetic polymer and 
poly(amino acid)s for nano-structure design and effort has been made to create structures that 
contain biologically relevant peptide sequences. Such sequences have a greater potential for 
interaction with biological environments and have begun to show some success. Synthesis of 
peptides and polypeptides for this purpose can be achieved by a variety of methods. 
With the aim of developing a method for producing well-defined, high-purity 
polypeptides, Solid-Phased Peptide Synthesis (SPPS) was first developed by Merrifield and 
coworkers
115
. The process involves using an N-protected amino acid, covalently linked to a solid 
support resin for the step-wise growth of the larger polypeptide. Deprotection of the supported 
amino acid yields the reactive N-terminal which can be used for coupling of the next sequential 
amino acid. SPPS thus involves repeated rounds of coupling and deprotection with purification 
(washing) after each cycle to produce carefully tailored polypeptides. Attachment of the 
polypeptide to the solid support during the synthetic process allows the desired product to be 
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retained during the washing cycles permitting high purity to be achieved. The final polypeptide 
product is obtained by removal of the solid resin. A number of amino acid protecting groups are 
commonly used including 9-fluorenylmethyloxycarbonyl (FMOC) and t-butyloxycarbonyl 
(BOC), each requiring different chemistries for deprotection. Due to the efficiency of its 
cleavage relative to the BOC, FMOC is known to give both higher purity and higher yield. 
 Although this method can be laborious recent advanced in technology mean it can be 
automated with a microwave-based peptide synthsizer. Additionally this method allows for 
production of high purity peptides resulting from the wash cycles performed after each amino 
acid addition. Unlike production of peptides by other methods, SPPS allows for total control over 
the peptide sequence and can be used for production of compound that may be difficult to 
produce by other means.  
 Although this method is widely used for production of smaller (< 50 amino acids) 
peptides, larger peptide sequences are not generally possible. As the peptide length increases the 
coupling efficiency decreases, meaning complex polypeptides cannot be prepared. Additionally, 
purity and solubility become increasingly challenging at higher molecular weights and can limit 
the length of the polypeptide prepared in this fashion. Finally, in all steps of this process it is 
necessary to utilize an excess of amino acid for the coupling resulting in increased usage of 
materials. Consequently, SPPS is generally only used for production of smaller polypeptide 
sequences
115
. 
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 For production of much larger polypeptide sequences or protein fragments, smaller 
segments are often synthesized separately and linked together by means of native chemical 
ligation
116
. This method allows for creation of large complex protein fragments by means of a 
chemoselective reaction between two unprotected peptide fragments. The reaction avoids the use 
of traditional peptide bonds by reacting a peptide-thioester with an unprotected cysteint residue 
on an adjacent peptide. This reaction produces a thioester intermediate product which is unstable, 
which rearranges to the stable amide bond (in place to the classical peptide bond).
116
  
 Native chemical ligation does not utilize large BOC or FMOC protecting groups and so 
many of the solubility and stability issues associated with SPPS are avoided allowing for larger 
polypeptides to be produced. Additionally, due to the chemoselective nature of the reaction, 
minimal byproducts are procuded. Apart from linking smaller peptide segments to produce larger 
ones, this method is also often employed to include unique functional groups in polypeptides that 
may not generally be available with traditional amino acids
117
. 
 The main advantages of this method are the possibility to produce very large 
polypeptides, the avoidance of protecting groups and typical solubility issues as well as the 
avoidance of unwanted by-products. In generally, this is a very simple reaction compared to 
production of peptides by SPPS, however as it is used for linking of smaller peptide fragments, 
this fragments must still be synthesized by other means
118
. 
Production of large (milligram) quantities of well-defined poly peptides has been a 
significant challenge with the previously discussed synthetic techniques. More commonly, for 
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large scale production synthesis can be performed by the ring-opening polymerization of a N-
carboxyanhydride functionalized amino acid. This technique is commonly used for production of 
poly(amino acids) and block copolymers based on polypeptides. ROP produced less well-defined 
macromolecules compared to SPPS or NCL, but can produce larger quantities more readily and 
enables the production of more unique molecular archetectures. In addition, for application in 
drug deliveray and nanostructure self-assembly ROP of a NCA is most commonly utilized
119
.  
This method has been used with success for production of a broad range of polypeptides and 
block copolymers from both natural and synthetic amino acids and analogues.  
The ROP of NCA generally proceeds through one of two mechanisms; the activated 
monomer mechanism or more commonly the amine mechanism.
119
 The primary difference 
between the two mechanisms is in their initiation, the former proceeding via a deprotonation and 
the later by nucleophilic substitution. ROP of NCA can proceed via two mechanisms: the normal 
amine mechanism (NAM, induced by nucleophilic substitution) and the activated monomer 
mechanism (AMM, induced by deprotonation). In both cases a relatively broad size-distribution 
is common resulting from the polymer propagation and chain growth. Narrow distributions are 
particularly difficult to achieve when high degrees of polymerization is required or when 
branched or complex architectures are designed, due to unwanted side reaction s which can also 
be initiated by amine groups or deprotonation. 
In recent years ROPs of NCAs have been attempted with a number of other mechanisms 
each with its own problematic drawbacks.
120
 Use of heavy metal catalysts results in a final 
product requiring intense purification to remove the metallic products, which can be time 
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consuming and difficult. Certain amine salts have been used such as hexamethyldisilazane 
(HMDS) amines, however they are highly sensitive to degradation and require stringent 
conditions for use. The most promising progress in this area has been the use of a BF4 primary 
amine as an initiator, as used by Coneios-Sanchez and coworkers.
121
 The use of this salt has 
allowed for production of large quantities of well-defined polypeptides resulting from the non-
neucleophilic character of the initiator salt. This method offers a great degree of control over the 
molecular weight, functionality and polydispersity.  
The opportunity to use functional non-natural polymers in combination with the scalable 
synthesis makes the ROP of NCA a great choice to reach well-defined polypeptides. Besides 
their multiple functionalities, adjustable Mws (1–1000 KDa) and structural homogeneity favor 
self-assembly into defined nanostructures with potential biomedical and pharmaceutical 
applications. One of the trends in the development of polymeric based nanomedicines is the 
building of well-defined, reproducible and homogenous architectures. Thus, the synthesis of 
narrowly distributed polypeptides for their potential use in biomedicine is a desirable goal. 
Several nano-scale systems based on polymer-peptide hybrid materials have recently 
been developed that use biologically relevant peptides within their nanostructures in order to 
interact with biological systems. To this end Jabbari et al produced nano-vesicles from the 
polymer-peptide hybrid V6K2-poly(lactic acid) (PLA)
7
. The V6K2 peptide is derived from 
intracellular proteins and incorporated into the polymer conjugate with the expectation of 
improving cellular uptake of the assembled particles. Nanoparticles assembled from these 
conjugates showed enhanced cellular uptake over a 24 hour period compared to that of analogous 
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PEG-b-PLA particles. Fluorescence imaging to the incubated cells is shown in Figure 6, where 
the drug loaded particle can be seen in green, localized in the cellular matrix. 
 
Figure 6 Fluorescence time lapsed micrographs of cellular localization of 
polymer-peptide hybrid particles
7
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With similar goals, Drappier et al were able to form nanoparticle from the HIV-
associated peptide sequence TAT, conjugated to the semi-crystalline polymer PTMC
4,128
. This 
sequence has been shown to enhance cellular uptake and was shown to form stable well defined 
nanoparticles. Such peptide-polymer hybrids show potential not only to increase interaction with 
biological systems, but also increase “stealth” capabilities, and potential to successfully cross the 
blood-brain barrier; a significant challenge in drug delivery systems
129
. Mathews et al 
successfully designed two conjugates RGDPAYQGRFL-b-poly(Ɛ-caprolactone) (PCL)-b-
poly(ethylene glycol) (PEO) and WXEAAYQRFL-b-PCL-b-PEO polymer-peptide hybrids, 
which showed extremely higher affinity for cancer cell lines than previously known tumor 
homing proteins, such as RDG-mimicking proteins
5
. Anti-cancer drugs could be directly 
conjugated to these structures or alternatively these structures could be used as encapsulating 
structures for storage and delivery of active ingredients. By this strategy, polymer-peptide 
hybrids can be exploited for enhanced targeting of nanostructures. 
Peptides are the natural substrates for biological enzymes and as such have been used 
with particular efficacy for development of enzyme-responsive nanostructures with potential 
applications in biomedicine. The peptide sequence AYL was coupled to a branched PEG 
polymer for production of a hydrogel. In the presence of the enzymes plasmin and trypsin the 
hydrogel was shown to selectively degrade.
130
 Conceptually, this idea can be extended for 
production of structures sensitive to a broad range of biological enzymes.  
The ability of certain peptides to form stable secondary structures has recently been 
exploited, to produce a micelle system capable of being cleaved by the biological enzyme 
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chymotrypsin. In this case the enzymatic substrate AAKLVFF, known to form stable β-sheets 
was coupled to a high molecular weight PEG to produce micelles. The peptide can be cleaved by 
chymotripsin for release of the peptide which can proceed to influence gene expression.  
As previously discussed the attachment of PEG provides a stealth feature to 
nanoparticles, improving the circulation time of PEGylated structures and reducing biological 
clearance. Extended circulation lifetimes result from reduced recognition by the host response 
system (reduced immunogenicity) and reduced enzymatic degradation. This concept has been 
widely employed in the development of therapeutic materials. 
The group of Kataoka conjugated P(asp) to PEG for production of polyionic micelles, 
having a highly charged character. Due to the charged nature of the micelle, oppositely charged 
drugs and payloads were shown to have a high affinity for the carrier through electrostatic 
interactions with the charged peptide block. Additionally, in aqueous solutions the charged 
enzyme lysozyme could become trapped in the micelles leading to the degradation of the 
structure. This affinity was further enhanced by addition of aromatic groups to the copolymer 
structure. In the case of this PEG-b-PAsp structure the presence of the charged peptide and the 
level of interaction between the peptide and the payload and enzyme were key to the structure 
function. 
Indeed the use of charged nanostructures based on polypeptides has been widely used for 
stabilization and enhanced affinity with specific enzymes and drugs. This technique has been 
utilized for enhancement of solubility of insoluble compounds and/or insoluble hydrophobic 
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molecules. PEG-SS-PAsp has been developed to not only enhance the solubility of the anticancer 
drug adriamycin,
131
 but additionally to provide a redox-sensitive release mechanism. Within the 
cytoplasmic environment the disulfide bridge linking the polymer and peptide could be 
selectively reduced by glutathione. Adriamycine showing strong interaction with the PAsp block 
through the electrostatics between the carboxyl unit of the peptide and the amine group of the 
drug. Such drug-carrier interactions are here greatly exploited for the benefit of the delivery 
system. In a similar redox-sensitive system, PEG-b-PLys and PEG-b-PAsp were complexed to 
form micelles and showed a reversible cross-linking in the presence of either reductive or 
oxidative conditions.
103
 
Likely, the most commonly used polypeptide is PGA, which has been widely used as a 
pH-sensitive block for polymer-peptide conjugates. Similar to poly(aspartic acid) diblocks, 
conjugates of PEG with poly-(glutamic acid) have been used for the delivery of the anticancer 
drug doxorubicin
65
. Following a similar concept, a hydrazone unit has been used as an acid-
sensitive linker to release adriamycin from PEG−p(Asp) conjugates in endosomes or lysosomes. 
Complexation of PEG−b-PGA−cholesterol conjugate with a platinum-containing anticancer 
agent leads to the formation of metal-containing polymersomes. 
For application in DNA therapy several polypeptide-based systems have been developed 
which take advantage of the high cationic charge of the well-known PLys. When conjugated to 
PEG this system has been shown to form micelles with long-circulation times, capable of 
binding (through electrostatic complexation) with plasmin DNA in vitro. PLL−PEG diblock 
copolymers have been used as micellar drug delivery systems for DNA, showing an increased 
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resistance to nucleases of plasmid DNA encapsulated in the core because of electrostatic 
interaction with PLL. A similar system based on Plys-b-PEG-b-Plys allowed for the stable and 
slow release of the drug paclitaxel from the formed charged micelles.
103
  
For applications in x-ray imaging nanoparticles assembled from PLL−b-PEG diblocks 
were shown to have extended circulation times. Photodynamic therapy has been proposed as a 
means to treat disease, such as cancer. The concept is based on first localizing nanoparticles at 
the site of diseased tissued and subsequently inducing toxicity via a light-triggered mechanism. 
PEG−b-PLL diblocks form charged ionic  micelles upon complexation with oppositely charged  
porphyrins. Porphyrins provide the structures with a high level of photodynamic efficiency 
which can be exploited intracellularly as a therapeutic structure. Micelle forming PEG−peptides 
incorporating synthetic peptides such as PBLG or PBLA have similarly been used to encapsulate 
a variety of poorly water-soluble drugs.
132
 PEG−b-PBLG diblocks have been observed to self-
assemble in aqueous solution, and the core of the micelles can be loaded with the benzodiazepine 
drug clonazepam. The release rate decreases with increasing PBLG chain length. A PEG−b-
PBLA diblock has been used to solubilize indomethacin, a nonsteroidal anti-inflammatory 
drug
133
. The release rate was found to increase with pH in the range 1.2−7.4. 
Drug Delivery Systems from Polymeric Nanostructures 
Two main factors make polymer vesicles particularly attractive as drug delivery vehicles. 
The first is their stability, which relative to analogous structures such as liposomes is 
comparatively long-term. Secondly, is the structure itself, comprised of two main regions; the 
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aqueous cavity and the hydrophobic membrane interior. As a result of this multi-compartment 
systems, polymer vesicles, similar to biological cells, can be used as carriers for hydrophobic, 
hydrophilic and amphiphilic molecules. Hydrophobic and amphiphilic molecules can be 
encapsulated within the hydrophobic region of the membrane with water-soluble molecules 
encapsulated in the aqueous cavity. Recent studies have seen a wide range of payloads loaded 
into the membranes of polymer vesicles, including dyes and quantum dots as well as molecules 
more relevant to drug delivery such as anticancer drugs and membrane proteins
20,21,60,134
. Such 
proteins and drugs have been shown to maintain their functionality regardless of encapsulation
60
.  
Encapsulation of drugs and other payloads can be localized within the aqueous cavity or 
membrane interior of polymer vesicles by a number of strategies. By incorporating the molecules 
into the organic phase along with the copolymer prior to vesicle formation, drugs can be 
encapsulated during the self-assembly process. This method can be used for encapsulation of 
both hydrophilic molecules in the aqueous cavity as well as hydrophobic molecules in the 
membrane interior. This method has been used successfully for encapsulation of drugs such as 
paclitaxel (PTX) and doxorubicin (DOX)
20,89
. In many cases polymer vesicles show comparable 
drug loading capacity to liposomes and in some cases have far exceeded traditional loading 
capacities
89
.  In addition to high loading capacity, polymer vesicles were shown to be much more 
stable than comparable liposome formulations. In addition to this coprecipitation technique, 
drugs can also be loaded into pre-formed vesicles by application of pH or salt gradient which 
drives the diffusion of drug molecules into the vesicle
135,136
.   
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The vesicle membrane acts as a physical (and in cases a chemical) barrier holding 
payloads within the structure. Drugs are released from the vesicle by a diffusive mechanism with 
the drugs crossing the vesicle membrane, driven by a concentration gradient with the external 
medium. In the simplest of cases, drug release from polymer vesicles is governed by diffusion, 
but can be strongly influenced by chemical interactions between the drug and copolymers used 
as well as by the localization of the drug within the vesicle structure
137,138
. Drug release has been 
shown to also be somewhat influenced by the size and distribution of the vesicle population. 
Spatial and temporal control of drug release can be controlled by selection of specific 
copolymers or changes to the environmental conditions of release.  
As discussed earlier, much research has focused on the use of stimuli-responsive 
materials for the production of “smart” polymer vesicles capable of controlled and/or triggered 
drug release
56,139
. To this end, vesicles with responses tunable to changing external environments 
have been developed. Most commonly, polymers have been used that are responsive to changes 
in local conditions such as temperature, pH, redox environment and glucose concentration as 
well as external conditions such as light, magnetic field or ionic strength. In general, strategies 
involving stimuli-responsive materials are used in order to trigger or enhance membrane 
permeability, disrupt the vesicle structure or alter the hydrophobic/hydrophilic characteristics of 
the copolymer structure in order to induce drug release. By exploiting stimuli-responsive 
vesicles, drugs can be stably encapsulated within the carrier and triggered to release only at a 
target site. This technology holds potential for site-specific drug delivery for reduction of 
therapeutic side-effects and enhancement of efficacy.  
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In drug delivery systems for biomedical applications, one of the most relevant stimuli is 
pH, due to the changing pH conditions throughout the body and in various cellular 
compartments. Particularly relevant for drug delivery systems are the acidic environments of 
cancerous tissues (pH 6.5-7.2) , endosomes (pH 5.0-6.5) and lysosomes (pH 4.5-5.0) which have 
been utilized for anticancer drug delivery and intracellular drug delivery
140,141
. pH-responsive 
systems are generally designed to encapsulate and remain stable at physiologically neutral pH 
(7.4) and to be triggered to release in the more acidic organs or organelles of the body
142
. 
Sensitivity to pH of a polymer is dependent on the presence of a titratable group (usually a 
carboxyl or amine function) along the polymer side-chains or within the polymer backbone. 
Changes in pH can protonate or deprotonate these functionalities triggering release of the 
payload. The critical pH of the copolymer is dependent on the pKa of the functional groups. 
Most commonly, a change in pH of the system will result in a disruption of the 
hydrophilic/hydrophobic balance of the copolymer, which is critical to the assembly of the 
system, resulting in structural disruption and triggered release. For example, PEG-b-poly(2-
vinylpyridine) (PEG-P2VP) vesicles can be completely solubilized at a pH below 5
95
. P2VP is 
insoluble in water under neutral and basic conditions, but soluble at acidic conditions. Similarly, 
PLys-b-poly(leucine) (PLys-b-PLE) vesicles showed a pH-dependent solubility and eventually a 
pH-triggered release
96
. Upon lowering the pH, PLys becomes protonated, leading to the 
solubilization of the membrane and the release of the encapsulated payload. 
In addition to disruption of the hydrophilic/hydrophobic balance, changes in pH can also 
induce cleavage of covalent bonds within the copolymer structure or cause alterations in the 
permeability of the vesicle membrane. These changes can be used to create a ‘burst’ release or to 
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modulate the release rate of encapsulated drugs. This strategy has been used to particular effect 
by Chen et al in creation of their DOX and PTX-loaded vesicles from PEG-b-poly(2,4,6-
trimethoxybenzylidenepentaerythritol carbonate) (PTMBPEC)
20
. The drug release could be 
modulated and enhanced by changing pH to affect the rate of degradation of the polymer 
backbone. Faster degradation occurred under low pH conditions resulting in a more rapid drug 
release. Reported “breathing” polymer vesicles based on a tri-block copolymer of PEG-b-PS-b-
(poly(2-diethylaminoethyl methacrylate), PDEAMA) showed pH-sensitive membrane 
properties
99
. In this case, the permeability and thickness of the membrane could be modulated 
under changing pH conditions due to increasing and decreasing electrostatic interactions between 
the titratable copolymer chains. Due to the presence of a rigid PS layer at the membrane interior 
no disassembly was observed, however, significant changes in the membrane thickness could be 
observed. Micrographs of this effect can be seen in Figure 7, showing the change in vesicle size 
between pH 10.4 and 3.4
99
. 
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Figure 7 (a) Cryo-TEM images of the vesicle wall at several pH values. (b) 
Membrane structure at corresponding pH values
99
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Figure 8 Schematic illustration of vesicles from PEG-b-PNIPAAm copolymer 
at 37 ºC and 25 ºC, respectively
143
 
Temperature as a stimulus is also of particular relevance in drug delivery due to the stable 
well-defined body temperature. Most commonly, thermo-responsive drug delivery systems have 
included the well known polymer PNIPAAm, which has been frequently used for production of 
stable polymer vesicles. As discussed earlier, the sharp phase transition temperature (LCST) of 
PNIPAAm close to human body temperature induces a coil to globule conformation change in 
the polymer resulting in a hydrophilic/hydrophobic transition. This property was exploited with 
particular effect by Qin et al
143
, who prepared stable vesicles by dispersing the full hydrophilic 
PEG-b-PNIPAAm copolymer in water and raising the system temperature above the LCST to 
induce assembly. This process was completely reversible with vesicle disassembly occurring 
when the temperature was once again reduced below the LCST. This process is shown 
schematically in Figure 8.  
In addition to pH and temperature, there are large changes in the redox environments of 
different cellular systems. Within extracellular environments, conditions are generally oxidative, 
however in inflamed tissues or within cancerous and intracellular compartments, reductive 
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conditions exist. This difference in microenvironment can be exploited by using redox-sensitive 
polymers for the design of drug delivery vesicles. Hubbell and co-workers developed oxidation 
responsive polymer vesicles based on PEG-b-poly(propylene sulfide)-b-PEG (PEG-b-PPS-b-
PEG)
106
. Over a two hour period, under oxidative conditions, the PPS layer was shown to 
destabilize due to oxidation, resulting in disruption of the nanostructure. This disruption could 
also be observed within cellular endosomes. 
In addition to systems that respond to specific stimuli, much research has been directed to 
systems that can respond to biological enzymes. Of particular interest are the cancer-associated 
enzymes matrix metalloproteinase (MMP) 2 and 9 which are known to be strongly associated 
with aggressive solid tumours
144,145
. These enzymes are found highly expressed in tumour tissues 
but in only low levels in healthy adult tissues. They thus represent an ideal target for a DDS. 
Additionally, MMP-2, 9 are known to selectively cleave the peptide proline-valine-glycine-
leucine-isoleucine-glycine (PVGLIG) between the gylcine and leucine residues
146
. 
Chau et al. used conjugates containing the PVGLIG peptide to demonstrate selective 
release of PTX in the presence of MMP-2, relative to conjugates containing a nonsense peptide 
or none at all
147,148
. The same conjugates were then able to preferentially localize PTX within 
tumor tissues in vivo. It is evident that the design of potential drug carriers and nanostructures 
which can incorporate PVGLIG offers a unique opportunity for drug targeting of the tumor 
microenvironment. 
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It is clear that for clinical applications of drug delivery systems it is desirable to use 
biocompatible and biodegradable polymers for vesicle formation. Approaches in triggered 
release have begun to exploit the biodegradable nature of some polymers in order to control the 
release rate of drugs. Biodegradation most commonly occurs via hydrolysis of the polymer, 
however the rate of hydrolysis is greatly dependant on the nature of the specific polymers 
chosen. By selecting specific biodegradable polymers, the rate of biodegradation can be 
controlled, in the presence of water or biological enzymes.  The most common biodegradable 
polymers used for this purpose are PLAs
129
, PCLs
149
, PTMC
40
 and PEG
56
, each showing unique 
hydrolysis rates under biologically relevant conditions.   
Passive and Active Targeting of Drug Delivery Systems 
Current chemotherapies suffer from a number of drawbacks which limit the efficacy and 
versatility of the treatment. The most significant disadvantage of these kinds of therapies is a 
lack of specificity. Traditional chemotherapeutic agents are administered to a patient 
intravenously, circulate throughout the body and interact with both cancerous and healthy 
tissues. Since the healthy tissues as well as cancerous tissues are exposed to the active agents 
(drugs), chemotherapy often results in significant and severe unwanted side effects for the 
patient, due to the damage caused to surrounding healthy tissues. The damage caused to healthy 
tissues limits the treatments in two significant ways. Firstly, due to the adverse effects of the 
drugs on the patient, treatment often needs to be stopped prematurely to avoid permanent 
damage to other healthy tissues. Secondly, the achievable drug dose in a tumour, for example, is 
limited by the damage being done to surrounding tissues. The drug dose at the target site may be 
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well below the dose required to successfully treat the cancer effectively. Current cancer therapies 
are thus greatly limited not by the drugs being used but by their lack of specificity. There is thus 
a need for targeting cancer therapy using a drug delivery system (DDS). 
Targeting drug delivery systems to tumour tissues can be broadly divided into two 
categories; passive targeting and active targeting. Passive targeting results from a size-based 
accumulation of particles in tumour tissues caused by the enhanced permeation and retention 
(EPR) effect
150–152
. This effect is a result of the unique physiology of cancer tissues compared to 
healthy adult tissues. The physiological difference is shown schematically in Figure 9 below. As 
cancerous tissues expand and grow very rapidly, their biological structures are comparatively 
underdeveloped. In healthy tissues, tight junctions within the walls of blood vessels prevent 
diffusion of everything but the smallest molecules into the surrounding tissues. Within rapidly 
expanding tumor tissues, however, the vessels are more leaky allowing for the diffusion of not 
only small molecules, but also large macromolecules and small structures. In addition, the lack 
of proper lymphatic vessels for drainage means that these particles cannot be removed 
effectively. As a result, there is a selective-accumulation of large molecules and small particles 
in tumor tissues. The EPR effect is seen in nearly all types of cancers which produce solid 
tumors, and can affect particles between approximately 20 and 200 nm
150
. This type of passive 
targeting allows DDSs to be concentrated in diseased tissues over time. The dose of the 
encapsulated drug is effectively enhanced in the immediate environment of the diseased cells, 
while simultaneously being reduced in the surrounding healthy tissues. While DDSs benefit from 
the EPR effect, it is only effective in limited types of diseased tissues (such as solid tumours). 
Consequently, additional targeting mechanisms must necessarily be investigated.   
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Figure 9 Schematic representation comparing transport in healthy tissues to 
the EPR effect seen in cancerous tissues.
150
 
 
Within the application of drug delivery systems, one of the primary concerns for 
development of stable, long-circulating carriers is the clearance of nanocarriers by the body’s 
immune system. Rapid clearance of nanocarriers will negate any designed therapeutic benefit. As 
45 
 
such, vesicles with “stealth” properties have been developed in order to avoid the body’s natural 
clearance mechanisms
78,153,154
. These mechanisms begin with adsorption of biological proteins 
called opsonins during a process called opsonisation. These proteins can then bind to receptors 
on the primary immune cells, mononuclear phagocytes (MPSs)
155
. The carrier can then be 
internalized and broken down by these immune cells. It is clear that strategies for creating long-
circulating vesicles must focus on avoiding of opsonisation. 
To this end, several delivery systems have been developed to reduce the capacity of 
proteins to adsorb on the carrier surface
154
. Strategies to achieve this have focused on introducing 
surface layers on the vesicle comprised of various hydrophilic polymers that are not contusive to 
protein adsorption. Such polymers include polysaccharides, poly(amino acid)s (and their 
derivatives), poly(hydroxyethyl methacrylate) (PHMA) and most commonly PEG
156–158
. Such 
polymers have been extensively studied for use in drug carriers due to the remarkable stealth 
properties they can impart on nano-vesicles. Structures produced with “stealth” polymers have 
been shown to minimize interaction with blood components such as opsonins. The effect of these 
polymers on protein interaction is however, dependent on several factors, including molecular 
weight, concentration and the conformation of the polymer block. A comprehensive study of 
protein adsorption and PEG molecular weight was performed and showed that increase 
molecular weight was correlated with decrease protein adsorption, and therefore longer 
circulation times in vivo
21. While it is clear that “stealth” materials have an important role to 
play, other factors such as particle morphology and surface charge may also have significant 
roles.  
46 
 
Interestingly, while the presence of PEG and other “stealth” polymers have been shown 
to increase circulation times in vivo, evidence has suggested that they may also limit the uptake 
of nanoparticles by all biological cells, due to reduced structure-cell interaction. Therefore the 
challenge moving forward is to design stable polymer vesicles with long-circulation times, 
without decreasing their ability to be internalized by target cells
21
. With this goal, several studies 
have focused on conjugation of actively targeted moieties to the surface of PEG-containing 
vesicles. Such molecules have included antibodies or antibody fragments or peptides recognized 
by internalization mechanisms of the target cells.  
By using a combination of the targeting strategies mentioned, Li et al designed polymer 
vesicles with both “stealth” capabilities based on the presence of a PEG brush, but also cell 
penetrating character by presentation of a biologically relevant peptide sequence
6
. Nano-vesicles 
assembled from PEG-b-PAsp, in which the PAsp is modified in order to complex with DNA 
fragments, with the tumor-associated peptide sequence GPLGVRG linking the two polymer 
blocks were shown to have long-circulation times. In the presence of MMP-2 active enzyme, 
were shown to shed their PEG brush and become internalized by cancer cell lines. The strategy 
used by Li et al is shown below in Figure 10. Such systems can circulate freely in biological 
systems and can be directed to release active payloads within cells upon internalization. In the 
context of drug delivery systems, such hybrid systems able to combine the characteristics of both 
synthetic polymers and naturally occurring, biologically relevant peptides offer the greatest 
potential for future clinical applications.  
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Figure 10 Strategy for exploitation of "stealth" characteristics and cellular 
internalization of polymer vesicles
6
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Chapter 3 Enzyme-Degradable Self-Assembled Nanostructures From 
Polymer-Peptide Hybrids 
Introduction 
In recent decades, amphiphilic block copolymers have garnered considerable interest for 
their ability to generate a broad range of self-assembled nanoscale structures
11–13,159
. With 
applications abound, considerable attention has been given to their use as drug delivery systems 
(DDS)
18,19
. The challenge in drug delivery has now become to move from polymers as “passive” 
materials to “active” ones where the material itself plays a functional role in the drug delivery 
process, via triggered release or imbuing environment-responsive attributes on the system
37
. To 
this end, poly(amino acids) have attracted significant interest due to their biocompatibility, 
stability and controlled secondary conformations
27
. These materials have been explored 
extensively in nanostructure formation to produce stable and responsive structures for controlled 
and triggered drug release
28
. Despite extensive research into poly(amino acid)-based systems, 
few self-assembled systems have been developed that incorporate biologically relevant peptides 
as both a structural and functional element
29,30
. Specific peptides that can act as cleavage 
substrates for highly selective enzymes offer an opportunity for the development of delivery 
vehicles with exceedingly specific degradation environments. 
Hybrid materials based on the conjugation between synthetic polymers and biologically 
relevant peptides have recently emerged as a new class of soft nanomaterials
28
. These hybrid 
materials are capable of combining characteristics and functionalities of both polymers and 
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peptides allowing for unique chemistry, properties, functionality, self-assembly and 
applications
160–169
. These materials are of particular relevance in biomedical applications such as 
biological scaffolding and drug delivery, due to the often inherent biocompatibility of 
biologically relevant peptides and poly(amino acids)
170–172
. By combining characteristics and 
functionalities of both peptides and synthetic polymers, these hybrid systems provide a path 
towards new biomimetic materials. 
 Several actively targeted DDSs have previously been developed that respond to certain 
stimuli in the disease microenvironment such as temperature, pH, redox conditions and 
enzymatic complement
6,35,36
. Recently, systems incorporating biologically relevant peptide 
sequences have been engineered with some success, such as V6K2-poly(lactic acid) (PLA) by 
Jabbari et al.
7
, Tat-b-PTMC by Drappier et al.
4,128
 and RGDPAYQGRFL-b-
Poly(caprolactone)(PCL)-b-poly(ethylene glycol) (PEO) and WXEAAYQRFL-b-PCL-b-PEO 
conjugates by Mathews et al.
5
 Of particular interest in targeted cancer therapy is the well-known 
tumor-associated enzymes matrix metalloproteinase 2 and 9 (MMP-2, MMP-9), known to 
selectively cleave the peptide sequence PVGLIG
146,148,173
. These enzymes are part of the 
collagenase family associated with the degradation of the extracellular matrix and tissue 
remodeling
144
. In healthy tissues they are normally found in high levels during embryonic 
development and reproduction. In adults, these enzymes are expressed in extremely low levels in 
healthy tissues, however they are present in relatively high concentrations in aggressive tumors, 
that degrade the extracellular matrix to allow for tumor expansion
144
. This offers an ideal target 
for DDS design, where the nanoparticle can be concentrated and selectively degraded in the 
tumor microenvironment.  
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 Chau et al. have previously demonstrated the cleavability of PVGLIG in the presence of 
MMP-2, -9 as well as the selective tumor accumulation of conjugates containing PVGLIG
147,148
. 
It is evident that the design of potential drug carriers and nanostructures which can incorporate 
PVGLIG offers a unique opportunity for drug targeting of the tumor microenvironment. 
 In this study, we demonstrate a versatile coupling of the MMP-sensitive, hydrophilic 
peptide PVGLIG to a hydrophobic and biodegradable polymer, namely, poly(trimethylene 
carbonate) (PTMC). We have utilized fast and easy UV-initiated thiol-ene chemistry to “click” 
ene-functionalized PTMCs of varying size to a thiol-containing version of PVGLIG. The 
subsequent hybrids were then self-assembled into nanostructures of differing morphology 
(vesicles, compound micelles and core-shell) depending on the polymer block-size. In addition, 
selective degradation of the nanostructures by MMP-2 is demonstrated. Such physiologically 
stable, self-assembled structures prepared from the biologically relevant peptide PVGLIG hold 
potential as both passively and actively tumor targeting drug delivery systems and offers an 
insight into the self-assembly properties of complex polymer-peptide hybrids. 
Experimental 
Materials 
Trimethylene carbonate (1,3-dioxane-2-one: TMC) was purchased from Boehringer Ingelheim 
and dried on magnesium sulfate in tetrahydrofuran (THF), sublimated and stored in a glove box 
prior to use. Allyl alcohol (99 %), 1,3-bis(2,6-diisopropylphenyl)-imidazol-2-ylidene (NHC, 97 
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%), cysteamine (95 %), 2,2-dimethyloxy-2-phenylacetophenone (DMPA, 99 %), Fmoc-rink 
amide MBHA resin (1.1 mmol/g loading capacity), (benzotriazol-1-
yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP, 98 %), triisopropylsilane (TIS, 
99 %), N,N-diisopropylethylamine (DiPEA, 99.5 %) and piperidine (99.5 %) were purchased 
from Sigma-Aldrich and used as received. All Fmoc-protected amino acid derivatives (99 %) 
were obtained from Iris Biotech. Active, human, recombinant matrix metalloproteinase-2 (MMP-
2) enzyme was purchased from Calbiochem. The enzyme was aliquoted and stored at -80 °C 
prior to use. 
Synthesis of ene-functionalized PTMCn 
 In a typical experiment, TMC was dissolved in dry THF (2 M) and added drop-wise to a 
solution of allyl alcohol (12 mM, 20 mM, 28 mM) and NHC (1 mM) in dry THF under inert 
atmosphere. The reaction was left stirring for 90 min at room temperature and quenched with 
methanol. PTMC was precipitated in ice-cold methanol and purified by centrifugation (10 min, 
8000 rpm). The degree of polymerization was measured by end-group analysis of 
1
H NMR 
spectrum. PTMC of DP 13, 21 and 33 were produced and dispersities were determined by SEC 
to be 1.08, 1.11 and 1.13, respectively, with yields of 85 %, 80 %, and 82 %, respectively. 
1
H 
NMR (DMSO, 400 Hz) δ(ppm)= 2.0 (C(O)OCH2CH2CH2OC(O)), 4.2 
(C(O)OCH2CH2CH2OC(O)), 4.59 (H2C=CH-CH2-), 5.29 (H2C=CH-CH2-), 5.89 (H2C=CH-CH2-
).  
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Synthesis of PVGLIG peptide 
The βAPVGLIGβAC (βAla-Pro-Val-Gly-Leu-Ile-Gly-βAla-Cys) (PVGLIG) peptide was grown 
and cleaved from the rink amide MBHA resin by traditional Fmoc/t-Bu solid phase chemistry. 
Briefly, the synthesis proceeded with successive rounds of deprotection and amino acid coupling. 
Coupling steps were performed using a solution of the Fmoc-protected amino acid (0.2 M), 
PyBOP (0.45 M) and DiPEA (2 M) in DMF for 40 min. Deprotection was performed with 
piperidine/DMF (1:4) and monitored by UV-Vis spectroscopy. The final peptide product and 
remaining protecting groups were cleaved from the solid support with a mixture of 
TFA/H2O/TIS (95/2.5/2.5). The peptide was precipitated in diethyl ether and purified by semi-
preparative RP-HPLC on a C18 column (Waters SunFire™ C18 5 µm, 10 x 250 mm). The 
structure was confirmed by 
1
H NMR and ESI-MS and HPLC. Theoretical molecular weight = 
798.44 g/mol, experimental m/z: [M+H]+ = 799.4. 
1
H NMR (Figure 14) (DMSO, 400 Hz) δ= 
0.95 (Combined 18 Leu, Ile and Val proton signal). Full synthetic scheme and chemical 
structures of all reagents used are shown in Figures 11 and 12 below. 
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Figure 81 General synthesis protocol for synthesis of a peptide by Fmoc 
chemistry 
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Figure 92 Chemical structure of all reaction reagents and amino acids used in 
preparation of PVGLIG 
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Polymer-peptide conjugation by thiol-ene click chemistry 
Coupling of the ene-functionalized PTMC with the thiol group of the C-terminal cysteine residue 
of PVGLIG was achieved by UV-initiated thiol-ene click chemistry. In a typical experiment, 
PTMC (DP 13, 21, 33) (1 eq, 5 mM), PVGLIG (2 eq, 10 mM) and DMPA (1 eq, 5 mM) were 
dissolved in minimal DMF and irradiated with UV light (λ = 365 nm) for 1 h with stirring. The 
coupled product (PTMC-b-PVGLIG) was precipitated in ice-cold acetonitrile, centrifuged out 
and dried overnight under vacuum. Successful coupling was confirmed by 
1
H NMR and SEC. 
1
H 
NMR (DMSO, 400 Hz) δ(ppm)= 0.95 (PVGLIG), 2.0 (PTMC backbone), 4.2 (PTMC 
backbone).  
Self-Assembly of diblock conjugates by nanoprecipitation 
Self-assembly of PTMCn-b-PVGLIG was performed via a nanoprecipitation method. PTMC-b-
PVGLIG (5 mg) was dissolved in DMSO (500 µL). With vigorous stirring (700 rpm), water (4.5 
mL) was added over 15 s. The nanoparticle suspension was then purified by dialysis against 
water over 3 days (MWCO = 13 000), with regular water changes. Structure morphology was 
probed with dynamic and static light scattering and TEM.  
1
H NMR.  
All measurements were done using a Brukner Adsvance spectrometer operating at 400 MHz. All 
measurements were carried out at room temperature with a fixed (7.5 s ) relaxation time. d-
DMSO was used as a reference signal (δ=2.5 ppm). 
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Size-exclusion chromatography 
 All SEC measurements were performed in dimethylformamide (DMF) with LiBr (1 g/L) as the 
eluent. The flow rate was fixed at 0.8 mL/min. Two 7.5 mm x 300 mm PLgel, 5 µm Mixed-D 
columns (Polymer Laboratories) were coupled to a guard column, 7.5 mm x 50 mm, PLgel, 5 µm 
(Polymer Laboratories). The system was equipped with a differential refractive index (RI) 
detector. Calibration was done with polystyrene standards. 
Dynamic light scattering (DLS) and static light scattering (SLS) 
DLS and SLS measurements were performed with a Brookhaven Laser Light Scattering system 
with a BI200SMv2 goniometer with a vertically polarized helium-neon diode laser at a 
wavelength of 636 nm and a BI-9000AT digital correlator with a 125 ns initial measurement 
time. Samples were kept at constant temperature (25 °C) for the duration of measurements. 
Measurements were taken every 10 ° between 60 ° and 140 °. SLS measurements were analyzed 
in a Berry plot to obtain the radius of gyration. 
Degradation of PTMCn-b-PVGLIG nanostructures by MMP-2 active enzyme 
Degradation of the assembled structures was performed in situ and conducted in DLS cells at 37 
°C. In a typical experiment active MMP-2 enzyme (10 nM) was added to suspensions of 
PTMCn-b-PVGLIG (n= 13, 21 or 33) self-assembled hybrids (10 µM) in buffer (50 mM Tris pH 
7.5, 10mM CaCl2, 0.2 M NaCl). Degradation of the structures was followed by monitoring the 
scattered intensity (that is directly proportional to the size and weight of the nanoparticles) 
measured by DLS at 90° over a 48 h period. 
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Transmission electron microscopy (TEM) 
TEM images were recorded with a Philips CM10 TEM microscope using a 60 keV acceleration 
voltage. Samples were prepared by depositing one droplet of the dispersed nanoparticles onto a 
carbon-formvar grid (200 mesh coated with copper) and allowed to dry. No additional staining 
was performed. 
Micro differential scanning calorimetry (µDSC) 
Thermograms were recorded using a VP-DSC Microcalorimeter from MicroCal, LLC. 
Measurements were performed on 0.8 mL of 10 mM solutions of dispersed nanoparticles. 
Solutions were first stabilized at 10 °C prior to scanning. Measurements were taken between 10 
°C and 60 °C with a scan rate of 20 °C/hour with 10 min isotherms at 10 °C and 60 °C. Two 
heating and one cooling scans were recorded. 
Synthesis of PTMCs, PVGLIG and PTMCn-b-PVGLIG Hybrids 
In order to produce a series of polymer-peptide hybrids, the PTMC and PVGLIG peptide 
precursors were synthesized separately and conjugated via thiol-ene click chemistry. The 
PVGLIG peptide was synthesized by traditional Fmoc/t-Bu solid phase chemistry with several 
additional amino acid residues. Namely, one β-alanine residue at both C- and N- terminal ends 
was included to act as a short spacer surrounding the Pro-Val-Gly-Leu-Ile-Gly cleavable 
sequence. A cysteine residue was also added at the C-terminal end to provide a thiol group 
suitable for the subsequent coupling to the polymer by thiol-ene reaction. The calculated 
molecular weight of the peptide was 798.44 g.mol
-1
. The ESI mass spectrum of peptide figured 
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two peaks at m/z= 799.4 and 821.5 corresponding to the monocharged hydrogen and sodium 
cations, (M+H)
+
 and (M+Na)
+
, respectively (Figure 13a). DLS measurements showed no 
aggregation of the isolated peptide. The 
1
H NMR spectrum of PVGLIG with peak assignments 
can be seen in Figure 14.  
PTMC was synthesized using a one-step, metal-free ring-opening polymerization (ROP) 
utilizing allyl alcohol as the initiator and 1,3-bis(2,6-diisopropylphenyl)-imidazol-2-ylidene, a 
particular N-heterocyclic carbene (NHC) as the organic catalyst, to yield the final ene-
functionalized polymer
174–176
.  
 
Figure 103 a) ESI-MS spectrum of purified PVGLIG peptide and b) HPLC 
trace of purified PVGLIG peptide 
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Figure 14 
1
H NMR spectrum of purified PVGLIG peptide (d-DMSO). Peaks 
from the backbone amine groups can be seen between 7 ppm and 8.5 ppm 
  
Prior to synthesis, several preliminary studies were done in order to optimize reaction 
conditions for future syntheses. The kinetics of the reaction was studied by taking aliquots at key 
time points during the reaction and performing end-chain analysis of the 
1
H NMR spectra 
obtained to determine the degree of polymerization (DP) and GPC to determine the respective 
polydispersity index (PDI). Figure 15 below summarizes the evolution of the polymer DP and 
PDI over time. It was observed that within 60 min the polymer could reach 88 % of the targeted 
DP and 90 % within 90 min. Further reaction time did not produce polymers closer to the target 
DP.  
 Interestingly, with increasing reaction time a consistent increase in PDI was observed by 
GPC. This increase continued even after polymerization of the main chains had stopped as seen 
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by the evolution of the DP during the same time course. The evolution of the degree of 
polymerization and the polydispersity can be seen in Figure 15. This increase in PDI is attributed 
to the formation of side-reaction products. The polymer is known to trans-esterify and this 
transester product can be seen on the 
1
H NMR. At longer reaction times the polydispersity 
increases due to this transesterification process. Because of this side reaction the choice was 
made to quench reactions after 1 hour to limit the formation of unwanted by-products.  
 
Figure 115 Evolution of the degree of polymerization over time (left). 
Evolution of the polydispersity of PTMC over reaction time (right) 
 
PTMCs with chain length of 13, 21 and 33 and monomer conversion of approximately 
88% (corresponding to one hour reaction time) and narrow dispersities (1.08, 1.11 and 1.13 
respectively) were thus synthesized. The SEC trace is shown in Figure 20 for PTMC13 as an 
example, revealing a low dispersity and monomodal distribution of PTMC chains. Longer 
reaction times led to increased trans-esterification side reactions
177
, which results in substantially 
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higher dispersities approaching 1.30. By limiting the reaction time, the dispersity value could be 
kept relatively low and molecular weight could be targeted with reasonable precision. Typical 
1
H 
NMR spectra of PTMC13, PTMC21 and PTMC33 are shown in Figures 16, 17 and 18 respectively 
in which the terminal protons of the ene-functional group can be detected as 2 signals on the 
spectra at δ = 5.32 and 5.81 ppm. In addition, a signal corresponding to the proton adjacent to the 
terminal hydroxyl group can be seen at δ = 3.48 ppm, confirming the terminal functionalization 
of PTMC chains. In subsequent coupling reactions, these peaks were used as a probe to account 
of the coupling to the peptide. No signal due to side reactions such as trans-esterification 
reactions was detected on the spectrum. Further evidence of the polymer structure and 
quantitative introduction of the ene moiety was provided by MALDI-TOF mass spectrometry 
(Figure 19), showing a single distribution of peaks, with a peak-to-peak mass increment of 102.1 
g/mol corresponding to the molecular weight of one TMC unit. Peaks appeared at m/z = 102.1n 
+ Mtermi + 23, n being the degree of polymerization, 23 the molecular weight of the sodium ion 
generated during the ionization process and Mtermi the molecular weight of allyloxy and ene end 
groups. 
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Figure 126 
1
H NMR spectra of a) PTMC13 and b) PTMC13-b-PVGLIG 
showing disappearance of the “ene” functionality and one-to-one coupling of 
PTMC13 and PVGLIG 
 
Figure 137 
1
H NMR spectra of PTMC21-b-PVGLIG 
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Figure 148 
1
H NMR spectra of PTMC33-b-PVGLIG 
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Figure 159 Full MALDI-TOF spectrum of PTMC13 
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Figure 20 SEC trace in DMF with a toluene flow marker of PTMC13 and 
PVGLIG prior to the coupling reaction and the PTMC13-b-PVGLIG 
conjugate product (RI detection). 
 
 The successful coupling of the different PTMC segments and PVGLIG was accomplished 
via a thiol-ene click reaction
178–180
 between the terminal ene-function of the PTMC and the thiol 
group of the cysteine residue of the peptide, used in excess (2 equiv.), as shown in Scheme 1. 
The excess of peptide was subsequently removed by extensive dialysis against water. The 
successful coupling between the PTMC and the peptide was confirmed by monitoring the 
disappearance of the “ene” peaks seen on the 1H NMR spectra, at δ = 5.32 and 5.81ppm, and the 
marked shift in retention time on the SEC trace (Figure 20). The presence of the PTMC 
backbone peaks and the peptide peaks in the 
1
H NMR of the coupled product after dialysis 
confirmed the successful coupling. 
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Scheme 1 Synthesis of PTMCn-b-PVGLIG coupling via UV-initiated thiol-ene 
“click” reaction 
Table 2 Characteristics of self-assembled polymer-peptide hybrid structures. 
(a) hydrophilic weight fraction of the conjugate, (b) radius of gyration, (c) hydrodynamic radius, 
(d) large compound micelles 
 
Hybrid ƒa(%) RG
b
 (nm) RH
c
 (nm) PDI RG/RH Structure 
PTMC13-
b-
PVGLIG 
38 73.7 68.8  0.19 1.05 Vesicle 
PTMC21-
b-
PVGLIG 
28 65.5 52.6 0.31 1.25 LCM
d
 
PTMC33-
b-
PVGLIG 
19.5 42.4 61.9 0.24 0.685 Core-shell 
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In addition, the integration of 
1
H NMR peaks shows a 1:1 ratio between PTMC and the 
peptide, indicating a one-to-one coupling. This UV-initiated “click” reaction thus provides a 
versatile method for coupling large macromolecules in non-stringent conditions. A series of 
polymer-peptide hybrids were then produced by coupling PVGLIG with PTMC of DP 13, 21 and 
33. 
Self-Assembly of PTMCn-b-PVGLIG Hybrids 
After self-assembly in aqueous solution by nanoprecipitation and purification by dialysis, the 
obtained nanoparticles were analyzed by DLS, SLS and TEM. The results obtained from the 
light scattering are summarized in Table 1. As a result of their unique hydrophilic weight fraction 
(ƒ), each of the hybrids formed stable, well-defined nanoparticles of differing 
morphology
13,17,181
. Complete DLS and SLS data can be found in Figure 21. All three self-
assembled particles showed narrow size distributions over multiple scattering angles; as well, the 
values of the decay constant (Γ) for all particles exhibited linear q2 dependence, the hallmark of 
purely diffusive motion related to the presence of spherical objects. Additionally, Berry plots 
generated from SLS data over a broad angle range displayed a linear relationship between (I
-1
)
-1/2
 
and q
2
. All three hybrid systems yielded stable and well-defined nanostructures.  
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Figure 2116 A) Distribution plots, B) Decay times and C) Berry plots for all 
hybrids using multi-angle DLS and SLS 
Careful examination of TEM micrographs of each hybrid nanostructure was also 
performed to determine the particle morphology. Typical micrographs are shown in Figure 22 
along with schematic representations of each nanostructure for visualization. Based on both the 
RG/RH ratios obtained by light scattering and TEM observations, one can conclude that PTMC13-
b-PVGLIG produced vesicles, while PTMC21-b-PVGLIG gave rise to large compound micelles 
(LCM) and PTMC33-b-PVGLIG produced core-shell particles. The hydrophilic weight fraction 
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(ƒ) of the hybrids was attributed entirely to the PVGLIG peptide, which had the same segment 
length in each conjugate. The change in ƒ resulted from the increasing size of the hydrophobic 
PTMC block. By varying the hydrophobic weight fraction of the conjugates, these hybrids self-
assembled into nanostructures of varying morphologies. Eisenberg and Discher
17
 have 
previously demonstrated the importance of ƒ in the morphology of self-assembled particles from 
flexible and neutral copolymers. In this study, similar effects were evidenced with the polymer-
peptide hybrids, with the peptide playing the role of a hydrophilic polymer block. The 
hydrophilic weight fraction of PTMC13-b-PVGLIG is 38 % and is consistent with a vesicular 
morphology and a cylindrical time averaged molecular shape of the diblock system. PTMC21-b-
PVGLIG and PTMC33-b-PVGLIG have a lower ƒ value and require denser packing of 
hydrophobic blocks within the nanostructure. As a result of the solvent displacement preparation, 
the assembled structures are not necessarily in thermodynamic equilibrium, allowing for highly 
dense regions of PTMC in the structures (seen as dark regions on the TEM images) compared to 
relatively less dense PVGLIG regions. 
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Figure 17 TEM micrographs and structural schematic of a) vesicle 
nanoparticles assembled from PTMC13-b-PVGLIG, b) Large compound 
micelle nanoparticles assembled from PTMC21-b-PVGLIG and c) core-shell 
nanoparticles assembled from PTMC33-b-PVGLIG. In the schematics PTMC 
is represented in green and PVGLIG in shown in blue. 
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In addition, the tendency for PTMC to crystallize could have a dominant influence in the 
self-assembly process, as previously reported
40,182
. The phase transitions (melting point, Tm, 
taken at the peak for simplicity) of each of the hybrid self-assembled structures have been 
measured in solution by µDSC thermograms (Figure 23, table 2). This crystallization observed 
with PTMC has a significant influence on the nanostructure morphologies, leading to structure 
morphologies not in line with the f values
70,183
. The extent to which this crystallization and the 
self-assembly method influences the structure morphology is currently under investigation. The 
nanoprecipitation process and the nature of PTMC, together allow for the hybrids with low ƒ to 
form the variety of nanostructure morphology observed. 
 
Figure 183 µDSC thermograms of three self-assembled hybrid conjugates 
during the first heating scan from 10 °C to 60 °C at a scan rate of 20 °C/hour 
after a 30 min isotherm at 10 °C. 
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Table 3 Thermal characteristics by µDSC of self-assembled hybrids. 
Conjugate Tm (°C) Melting Enthalpy 
(J/g)
a
 
Melting Enthalpy 
(J/mol) 
PTMC13-b-PVGLIG 35.3 4.57 5.94 
PTMC21-b-PVGLIG 34.9 2.45 5.15 
PTMC33-b-PVGLIG 34.7 2.68 8.84 
 
(a) Normalized to PTMC mass in the conjugate 
 
Degradation of Hybrid Particles by MMP-2 
Enzymatic degradation was monitored by DLS by measuring the reduction in the scattered light 
intensity over time, which was correlated with a decrease in particle concentration and molecular 
weight. PTMCn-b-PVGLIG nanostructures were subjected to degradation by MMP-2 active 
enzyme over a period of 48 hours, which is known to specifically cleave the PVGLIG peptide 
between the glycine and leucine residues
146
. Dynamic light scattering measurements at 90° were 
taken at t = 0, 24 h and 48 h. The resulting decrease in the scattering intensity is shown in Figure 
24.  
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 All the particles (core-shell, LCM and vesicles) displayed significant degradation after 24 
and 48 hours. Scattering intensity was below 30 % of the initial for both the core-shell and LCM 
particles formed from PTMC33-b-PVGLIG and PTMC21-b-PVGLIG, respectively, but it was 
significantly higher (near 60 %) in the case of vesicles formed from PTMC13-b-PVGLIG. This 
might be due to the presence of cleavable PVGLIG at both the exterior and interior surfaces of 
the vesicles. It is likely that the peptide at the interior surface of the vesicles is not highly 
accessible to MMP-2 and is not cleaved by the enzyme. PTMC13-b-PVGLIG vesicles in buffer, 
without the presence of MMP-2, were used as a control to support the stability of the vesicles in 
solution. In addition, vesicles from a previous study assembled from PTMC30-b-PGA13
40
 in the 
presence of MMP-2 were used as a negative control. The lack of degradation observed of the 
Figure 19 Light-scattering intensity variation during degradation of 
PTMC13-b-PVGLIG, PTMC21-b-PVGLIG and PTMC33-b-PVGLIG 
nanostructures by MMP-2 active enzyme. PTMC30-b-PGA13 vesicles in the 
presence of MMP-2 are used as a control. PTMC13-b-PVGLIG vesicles with 
no enzyme present are used as a negative control. 
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PGA poly(amino acid) by MMP-2 supports the selectivity of the enzyme towards the PVGLIG 
peptide. 
TEM images were taken of each of the three structures after degradation by MMP-2, in 
order to confirm the structure disruption. The obtained images can be seen in Figure 25 and show 
significant loss of structure in all three cases. Cleavage of the peptide sequence results in loss of 
a portion of the hydrophilic weight fraction. This post-assembly modification results in 
instability of the structures and disassembly and aggregation of the system. In the case of the 
vesicles, some structures appear to be partially intact. This is likely due to the reduced 
degradation in the vesicles. 
 
Figure 205 TEM micrographs of degraded vesicles (left), LCMs (center) and 
core-shell (right) structures after extended incubation with MMP-2 active 
enzyme 
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Conclusions 
 
A combination of organo-catalyzed ring-opening polymerization, peptide synthesis and 
thiol-ene click chemistry was used to successfully access various structurally well-defined 
polymer-peptide hybrids comprised of PTMC and the MMP-2 peptide substrate PVGLIG. Click 
chemistry was used to couple the as-made PVGLIG peptide to varying block length PTMC 
featuring a terminal ene functional group to form the PTMC-b-PVGLIG hybrids. The 
amphiphilic nature of the di-block system allows for the self-assembly of PTMCn-b-PVGLIG by 
nanoprecipitaiton yielding stable monodispersed structures of varying morphology. With the 
enzyme-cleavable peptide as a structural element in the hybrids, these particles are selectively 
degradable by the tumor-associated enzyme MMP-2. Significant disruption of all structure 
morphologies was observed after incubation with MMP-2 over a 48 h period. These MMP-
sensitive structures represent the first step towards a targeted drug delivery system for the tumor 
microenvironment. The unique morphologies provide valuable insight into the mechanism of 
self-assembly of complex polymer-peptide hybrid molecules. 
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Chapter 4 Tailored Drug-Release from Multi-Block Polymer-Peptide Hybrid 
Vesicles 
Introduction 
 Amphiphilic block copolymers have been the dominant class of materials of interest for 
an increasingly broad range of applications in nanotechnology including health science, 
technology, energy and informatics
11–13,17,184
. Their prevalence in these fields stems from the 
unique and wide range of properties achievable by varying the chemistry and types of polymers 
used as well as their innate ability to self-assemble into a variety of particle morphologies.  
Specifically, stimuli-responsive materials have gained particular interest due to their ability to 
respond selectively to the varying conditions of living organisms
18,19
. Structures assembled form 
this class of materials have been shown to respond to changes in temperature, pH, oxidation 
conditions as well as chemical and enzymatic environments
6,35,36,88,139,142,164
. 
 Among block copolymers, those consisting of poly(amino acid)s are particularly 
attractive and have been exploited to more closely mimic biological systems. Several such 
synthetic polypeptide-based copolymers have recently been developed, but are limited in their 
ability to interact with biological systems
28,29,168,183
. To address this issue, recently, many self-
assembled systems, which seek to move one step further by incorporating biologically relevant 
molecules as structural elements, have been developed
4–7
. Such approaches represent a new step 
towards bio-mimicry and show great promise within nanomedicine.  
 Hybrid systems comprised of synthetic polymers and biologically relevant polypeptides 
can be tailored to be multi-functional, responding to multiple stimuli in a concerted manner. 
77 
 
They exploit the unique properties of each structural block to create a multi-functional self-
assembled system
1,181
. 
 Within this context this study seeks to engineer a triblock hybrid system consisting of the 
synthetic polymer poly(trimethylene carbonate) (PTMC)
45
, the poly(amino acid) poly(glutamic 
acid) (PGA)
89
, and the biologically relevant peptide Pro-Val-Glu-Leu-Ile-Glu (PVGLIG)
146
. 
PTMC is a semi-crystalline polymer which has been used extensively in self-assembled systems. 
Due to its melting temperature, structures assembled from this polymer show temperature 
sensitivity within biologically relevant ranges
45
. PGA is a poly(amino acid) with a pH-sensitivity 
due to its change in protonation state associated with a change in conformation
40,89,185,186
. Finally, 
the PVGLIG peptide is one of the known substrates for the tumour associated enzyme MMP-2, 
and has been used with success to disrupt nanostructures and localize conjugates within tumor 
microenvironments
3,146–148
. This system is capable of self-assembling into stable vesicles which 
show responsive drug release, sensitive to temperature, pH and the tumor-associated enzyme 
matrix metalloproteinase 2 (MMP-2)
145,147,148
. This multi-responsive property arises from the 
sensitivities of each individual block.  
  
Experimental 
Materials 
Trimethylene carbonate (1,3-dioxane-2-one: TMC) was purchased from Boehringer Ingelheim 
and dried on magnesium sulfate in tetrahydrofuran (THF), recrystallized and stored in a glove 
box prior to use. Allyl alcohol (99 %), 1,3-bis(2,6-diisopropylphenyl)-imidazol-2-ylidene (NHC, 
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97 %), cysteamine (95 %), 2,2-dimethyloxy-2-phenylacetophenone (DMPA, 99 %), Fmoc-rink 
amide MBHA resin (1.1 mmol/g loading capacity), (benzotriazol-1-
yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP, 98 %), triisopropylsilane (TIS, 
99 %), N,N-diisopropylethylamine (DiPEA, 99.5 %), piperidine (99.5 %) and imipramine 
hydrochloride (IMI, 99 %) were purchased from Sigma-Aldrich and used as received. All Fmoc-
protected amino acid derivatives (99 %) and γ-benzyl-L-gluatmate N-carboxy anhydride (BLG-
NCA) were obtained from Isochem France and used as received. Hydrobromic acid (HBr, 33 wt 
%), was purchased from Acros Organics and used as received. Trifuoroacetic acid (TFA, 99.9 %) 
was purchased from Caledon Laboratory Chemicals. For synthesis, dimethylformamide (DMF) 
and tetrahydrofuran (THF) were dried prior to use, all other solvents were used as received. 
Active, human, recombinant matrix metalloproteinase-2 (MMP-2) enzyme was purchased from 
Calibiochem. The enzyme was aliquoted and stored at -80 °C prior to use. 
Synthesis of ene-functionalized PTMC50 
Ene-functionalized PTMC50 was synthesized according to a previously described method
3
. 
Briefly, recrystalized TMC was dissolved in dry THF (2 M) and added drop-wise to a solution of 
allyl alcohol (45 mM) and 1,3-bis(2,6-diisopropylphenyl)-imidazol-2-ylidene (NHC) (1 mM) in 
dry THF under inert atmosphere. The reaction was left stirring for 90 min at room temperature 
and quenched with methanol. PTMC50 was precipitated in ice-cold methanol and purified by 
centrifugation. The degree of polymerization was measured by end-group analysis of 
1
H NMR 
spectrum. PTMC50 was produced with a polydispersity of 1.15 at a yield of 88 %. 
1
H NMR 
(DMSO-d6, 400 Hz) δ(ppm)= 2.0 (quintuplet) (C(O)OCH2CH2CH2OC(O)), 4.2 (triplet) 
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(C(O)OCH2CH2CH2OC(O)), 4.59 (doublet) (H2C=CH-CH2-), 5.29 (multiplet) (H2C=CH-CH2-), 
5.89 (multiplet) (H2C=CH-CH2-). 
Synthesis of PVGLIG peptide 
PVGLIG was synthesized according to a previously described method
3. The βAPVGLIGβAC 
(βAla-Pro-Val-Gly-Leu-Ile-Gly-βAla-Cys) (PVGLIG) peptide was grown and cleaved from a 
solid resin by traditional Fmoc/t-Bu solid phase chemistry. Briefly, the synthesis proceeded with 
successive rounds of deprotection and amino acid coupling. Coupling was done by washing of 
the deprotected peptide (or resin in the case of the first amino acid addition) with a solution of 
the protected amino acid (0.2 M), PyBOP (0.45 M) and DiPEA (2 M) in DMF for 40 min. 
Deprotection of the resin and peptide was confirmed by UV-Vis spectroscopy and coupling was 
confirmed by testing for primary amines (TNBS test). The final peptide product and any 
remaining protecting groups were cleaved from the solid support with a mixture of 
TFA/H2O/TIS (95/2.5/2.5). The peptide was precipitated in diethyl ether and purified by semi-
preparative RP-HPLC on a C18 column (Waters SunFire™ C18 5 µm, 10 x 250 mm). The 
peptide was characterized thoroughly in previous chapters and the 
1
H NMR with all peaks 
assigned is given in Figure 14. (DMSO, 400 Hz) δ= 0.95 (Combined 18 Leu, Ile and Val proton 
signal).  
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Polymerization of BLG-NCA from PVGLIG macroinitiator 
PBLG was grown from the amine terminus of PVGLIG via ROP using the peptide as a 
macroinitiator. In a glove box under inert conditions, BLG-NCA (225 mM) and PVGLIG (15 
mM) were dissolved in dry DMF and left stirring for 48 h. The solution was removed from the 
glove box and PVGLIG-b-PBLG15 was precipitated in diethyl ether. The precipitate was 
removed by centrifugation (10 min, 8000 rpm) and washed repeatedly with diethyl ether. The 
final product was dispersed in water and put on dialysis (MWCO = 2500), to remove any 
remaining PVGLIG, for 3 days with frequent changes of dialysis media. The final PVGLIG-b-
PBLG15 was freeze dried to obtain a white powder. 
1
H NMR (DMSO-d6, 400 Hz) δ= 7.18 (d) 
5H, C(O)CH[(CH2)2C(O)OCH2Ph]; δ= 5.09 (m) 2H, C(O)CH[(CH2)2C(O)OCH2Ph]; δ= 4.41 (m) 
1H, C(O)CH[(CH2)2C(O)OCH2Ph]; δ=2.45 (m) 2H, C(O)CH[(CH2CH2)C(O)OCH2Ph]; δ=1.95 
(m) 2H, C(O)CH[(CH2CH2)C(O)OCH2Ph]; δ= 0.95 (m) 18H, PVGLIG. 
Acid hydrolysis of PVGLIG-b-PBLG15 to PVGLIG-b-PGA15 
The benzyl side chain of PVGLIG-b-PBLG15 was cleaved by acid hydrolysis to produce 
PVGLIG-b-PGA15. In a typical cleavage experiment PVGLIG-b-PBLG15 (50 mg) was dissolved 
in TFA (3 mL) and HBr (50 µL) and left stirring for 2 h. PVGLIG-b-PGA15 was precipitated in 
diethyl either and isolated by filtration. The product was dissolved in water and purified by 
dialysis (MWCO = 1200 Da) against water for 2 days with frequent water changes. The final 
PVGLIG-b-PGA15 product was freeze dried to produce a white powder. 
1
H NMR (DMSO-d6, 
400 Hz) δ= 4.41 (m) 1H, C(O)CH[(CH2)2C(O)OH]; δ=2.45 (m) 2H, 
81 
 
C(O)CH[(CH2CH2)C(O)OH]; δ=1.95 (m) 2H, C(O)CH[(CH2CH2)C(O)OH]; δ= 0.95 (m) 18H, 
PVGLIG. 
Coupling of PVGLIG-b-PGA15 to PTMC50 via thiol-ene click chemistry 
Coupling of the ene-functionalized PTMC50 with the thiol group of the cysteine residue of 
PVGLIG-b-PGA15 was achieved via a previously developed method
3
, by UV-initiated thiol-ene 
click chemistry. PTMC50 (1 eq, 5 mM), PVGLIG-b-PGA15 (2 eq, 10 mM) and DMPA (1 eq, 5 
mM) were dissolved in DMF (3 mL) and irradiated with UV light (λ = 365 nm) for 120 min with 
stirring. Additional initiator was added consistently using a syringe pump loaded with DMPA (3 
mL, 5 mM) at an injection rate of 1.5 mL/h. The coupled product (PTMC50-b-PVGLIG-b-
PGA15) was precipitated in water. Unreacted PTMC50 was removed by precipitating the reaction 
mixture in water followed by burst centrifugation (1 min  at 2000 rpm). The unreacted PTMC50 
readily precipitates out of solution leaving a cloudy suspension, which was dialysed against 
water for 3 days (MWCO = 12 000) with regular changes to remove any excess PVGLIG-b-
PGA15. The final product was freeze-dried to produce a powder at 18 % yield. Successful 
coupling was confirmed by 
1
H NMR and GPC. 
1
H NMR (DMSO-d6, 400 Hz) δ= 4.41 (m) 1H, 
C(O)CH[(CH2)2C(O)OH]; δ= 4.2 (s) 4H (C(O)OCH2CH2CH2OC(O)); δ=2.45 (m) 2H, 
C(O)CH[(CH2CH2)C(O)OH]; δ= 2.0 (s) 2H (C(O)OCH2CH2CH2OC(O)); δ=1.95 (m) 2H, 
C(O)CH[(CH2CH2)C(O)OH]; δ= 0.95 PVGLIG.  
Vesicle self-assembly and drug encapsulation by nanoprecipitation 
Self-assembly of imipramine-loaded vesicles from PTMC50-b-PVGLIG-b-PGA15 was performed 
via a previously reported nanoprecipitation method
40
. PTMC50-b-PVGLIG-b-PGA15 (10 mg) and 
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imipramine hydrochloride (35 % feed weight ratio) were dissolved in DMSO (500 µL). With 
vigorous stirring (700 rpm), buffer pH = 9 (4.5 mL) was added over 15 s. The nanoparticle 
suspension pH was reduced by dialysis against buffer pH 7.4 over 30 min (MWCO = 13 000), 
with one buffer change. The dialysed mixture was purified by 3 rounds of ultrafiltation (pore size 
25 nm) and dispersion and the volume was reduced to 2 mL (5 mg/mL). Structure morphology 
was probed with dynamic and static light scattering and TEM. Drug loading was measured by 
UV-Vis Spectroscopy to be 37 % by monitoring wavelength 309 nm. The UV-Vis spectrum and 
structure of the free drug is shown in Figure 26, with a strong absorption band clearly visible. 
 
Figure 216 UV-Visible absorption spectrum of free IMI in water with 
molecular structure. Strong absorption band can be seen at 309 nm 
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Degradation of PTMC50-b-PVGLIG-b-PGA15 vesicles by MMP-2 active enzyme 
Degradation of the assembled vesicles was performed in situ and conducted in DLS cells at 37 
°C. In a typical experiment active MMP-2 enzyme (10 nM) was added to suspensions of 
PTMC50-b-PVGLIG-b-PGA15 self-assembled vesicles (10 µM) in buffer (50 mM Tris pH 7.5, 10 
mM CaCl2, 0.2 M NaCl). Degradation of the structures was monitored by following the change 
in scattering intensity by DLS at 90° over a 120 h period. 
Drug release measurements 
Drug-loaded vesicles were taken in a cellulose dialysis tube (MWCO: 12 000 g/mol). The 
dialysis tube, containing 5 mL of IMI-loaded vesicles (0.3 mg/mL) solution was introduced into 
in vitro release medium containing 50 mL Tris buffer (10mM Tris, pH 7.4). The assemblies were 
kept at different temperatures (15 °C, 22.5 °C, 26 °C, 38 °C, 45 °C and 55 °C) measured in the 
dialysis tubes and two pH values (pH 7.4 and pH 5.5 (37 °C)) during release. For release study at 
pH 5.5, the pH of the IMI-loaded vesicle solution was adjusted just after dialysis by adding 
concentrated HCl. Then, 5 mL of this solution was introduced into in vitro release medium 
containing 50 mL Acetate buffer (10 mM Acetate, pH 5.5). In all cases, sink conditions were 
maintained by replacing 2 mL of the release medium with fresh media at each sampling point. 
The amount of drug released was estimated from the measurement of the residual drug in the 
vesicles at each sampling point by spectrophotometry measurements (λ = 251 nm) of an aliquot 
taken outside the dialysis bag. The drug concentration could be directly calculated from the 
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measured absorbance by comparison to a prepared calibration curve. The amount of drug 
released was calculated from the amount of drug initially present in the vesicles and the amount 
of drug retained in the vesicles at each sampling point. Each experiment was carried out in 
duplicate and average values plotted. 
Size-exclusion chromatography 
All SEC measurements were performed in dimethylformamide (DMF) with LiBr (1 g/L) as the 
eluent. The flow rate was fixed at 0.8 mL/min. Two 7.5 mm x 300 mm PLgel, 5 µm Mixed-D 
columns (Polymer Laboratories) were coupled to a guard column, 7.5 mm x 50 mm, PLgel, 5 µm 
(Polymer Laboratories). The system was equipped with a differential refractive index (RI) 
detector. Calibration was done with polystyrene standards. 
1
H NMR 
All measurements were done using a Brukner Advance spectrometer operating at 400 MHz. All 
measurements were carried out at room temperature with a fixed (7.5 s ) relaxation time. DMSO-
d6 was used as a reference signal (δ=2.5 ppm). 
UV-Visible spectroscopy 
Measurements of drug release concentration were taken using a Varian (Carey 100 Bio) UV-
Visable spectrophotometer. Drug concentrations were determined by comparing absorbance 
values at the drug absorbance peak to a calibration curve. Total drug release was considered to 
be 100 % based on encapsulation efficiency measured. 
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Dynamic light scattering (DLS) and static light scattering (SLS) 
DLS and SLS measurements were performed with a Brookhaven Laser Light Scattering system 
with a BI200SMv2 goniometer with a vertically polarized helium-neon diode laser at a 
wavelength of 636 nm and a BI-9000AT digital correlator with a 125 ns initial measurement 
time. Samples were kept at constant temperature (25 °C) for the duration of measurements. 
Measurements were taken every 10° between 60° and 140°. SLS measurements were analyzed in 
a Berry plot to obtain the radius of gyration. 
Transmission electron microscopy (TEM) 
TEM images were recorded with a Philips CM10 TEM microscope using a 60 keV acceleration 
voltage. Samples were prepared by depositing one droplet of the dispersed nanoparticles onto a 
carbon-formvar grid (200 mesh coated with copper) and allowed to dry. No additional staining 
was performed. 
Micro differential Scanning calorimetry (µDSC) 
Thermograms were recorded using a VP-DSC MicorCalorimeter from MicroCal, LLC. 
Measurements were performed on 0.8 mL of 10 mM solutions of dispersed nanoparticles. 
Solutions were first stabilized at 10 °C prior to scanning. Measurements were taken between 10 
°C and 60 °C with a scan rate of 20 °C/hour with 10 min isotherms at 10 °C and 60 °C. Two 
heating and one cooling scans were recorded. 
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Synthesis of PVGLIG, polymers and tri-block Hybrid 
With the aim of targeting a vesicle structure with a final hydrophilic weight fraction of 35 
%
17
, PVGLIG peptide was synthesized and used as a macromolecular initiator for the ROP of 
BLG-NCA to produce PVGLIG-b-PBLG15. PVGLIG-b-PGA15 was produced by acid hydrolysis 
of the PBLG benzyl function. Finally, ene-functionalized PTMC50 was coupled to the thiol 
function of the cysteine residue of PVGLIG to produce the final PTMC50-b-PVGLIG-b-PGA15 
triblock system. The complete synthetic strategy can be seen in scheme 2 below. 
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Scheme 2 Synthetic strategy for PTMC50-b-PVGLIG-b-PGA15 
The synthetic strategy relies on a sequence order to grow and couple multiple blocks into 
a single copolymer. This strategy required specific functionalization of each block, including 
addition of the thiol-containing cysteine residue to PVGLIG and the ene-functionalization of the 
PTMC block. In addition, the N-terminus of the PVGLIG peptide was required for initiation of 
the ring-opening of the BLG-NCA monomer. Deprotection of the carboxyl group by TFA/HBr, 
was done prior to coupling with PTMC in order to avoid any degradation of the PTMC back 
bone, which is also susceptible to hydrolysis in highly acidic environments. 
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The PVLGIG peptide was synthesized and well characterized based on a previously 
reported study. Briefly, the PVGLIG peptide was synthesized by traditional Fmoc/t-Bu solid 
phase chemistry. β-Alanine residues at both C- and N- terminal ends were included as spacers 
surrounding the PVGLIG cleavable sequence. A cysteine residue was also added at the C-
terminal end to provide a thiol group suitable for the subsequent coupling to the polymer by 
thiol-ene reaction
179
.  
PVGLIG peptide was used as an initiator for the ROP of BLG-NCA. By adjusting the 
PVGLIG:BLG-NCA ratio a block length of 15 was targeted successfully with a reaction time of 
48 h. The monomer conversion was > 90 % over the full reaction time, allowing for easy 
targeting of specific molecular weights. Unreacted monomer was removed by precipitation of the 
conjugate in diethyl ether. The product was dried and dispersed in water. In order to remove any 
unreacted PVGLIG, the mixture was put on dialysis against water for 3 days with frequent water 
changes. The purified product was freeze-dried to produce a white powder. 
In the 
1
H NMR spectrum of PVGLIG-b-PBLG15 seen in Figure 27, a signal can be seen 
at 0.95 ppm corresponding to the side-chain methyl and ethyl protons of the peptide val, leu and 
ile residues. The presence of this signal after dialysis is indicative of PVGLIG with polymerized 
PBLG15. Additionally, the benzyl side chain from the PBLG produces two strong signals at 5.05 
ppm and 7.2 ppm. Additional signals from the PBLG backbone and side chain can be observed 
in the 
1
H NMR (Figure 27).  PVGLIG-b-PGA15 was subsequently produced by acid hydrolysis 
of the benzyl side-chains of the PBLG block, followed by precipitation in diethyl ether, filtration 
and multiple rounds of washing with diethyl ether. The loss of the benzyl groups can be observed 
by monitoring the disappearance of the corresponding 
1
H NMR peaks at 7.2 and 5.05ppm , seen 
in Figure 27. 
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Figure 227 
1
H NMR spectra in DMSO-d6 at 400 Hz (from top to bottom) of 
PVGLIG, PVGLIG-b-PBLG15, PVGLIG-b-PGA15, PTMC50-b-PVGLIG-b-
PGA15 after purification at each step, showing the step-wise synthesis of the 
final triblock conjugate 
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PTMC50-b-PVGLIG-b-PGA15 was produced by a UV-initiated thiol-ene coupling 
reaction between the terminal ene function of the PTMC and the cysteine residue of the 
PVGLIG-b-PGA15. Similar reactions had been performed in a previous study with some 
success
3
; however, due to the increased size of the two macromolecular blocks, initial attempts at 
the reaction resulted in extremely low yield. As a result of the large molecular weight, the 
reactive ends have limited accessibility. In addition, the reactive radical produced by the initiator 
has an extremely short life-time, also contributing to a poor yield. To aid the reaction, a constant 
supply of DMPA initiator was supplied to the reaction mixture gradually for the duration of the 
reaction. This process allowed increased exposure of the blocks to the reactive radical initiator 
resulting in a reaction yield of 18 %, higher than previously achieved. Unreacted PTMC50 was 
removed by successive rounds of precipitation in water and centrifugation. Unreacted PVGLIG-
b-PGA15 was removed by dialysis against water. The 
1
H NMR spectrum (Figure 27) of the final 
product shows the presence of peaks corresponding to the backbone protons of PTMC50 at 2.00 
ppm and 4.00 ppm, as well as the peaks previously observed for PVGLIG-b-PGA15. 
Figure 28 shows the SEC traces for all products produced. A narrow size-distribution of 
the PTMC50 and PVGLIG-b-PGA15 precursors can be observed. The triblock showed a clear 
shift to lower elution time, with no trace from the two isolated blocks, evidencing the success of 
the coupling and purification steps. 
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Figure 238 SEC traces of PVGLIG-b-PBLG15, PVGLIG-b-PGA15 and 
PTMC50-b-PVGLIG-b-PGA15 showing the step-wise production of the final 
triblock copolymer in DMF, measured with a refractive index detector. 
 
Self-Assembly and Characterization of PTMC50-b-PVGLIG-b-PGA15 Tri-block 
Vesicles and Degradation by MMP-2 
After self-assembly by nanoprecipitation, vesicles produced by the triblock conjugate 
were isolated by dialysis and analyzed by DLS, SLS and TEM imaging. Light scattering 
measurements showed a RG value of 86 nm and an RH of 94 nm giving a RG/RH of 0.92, that can 
be consistent with a vesicle morphology. The structures showed narrow size distributions over 
multiple scattering angles and linear q
2
 dependance of the decay constant and (I
-1
)
-1/2
 (the 
complete data set from DLS and SLS measurements can be found in Figure 29). TEM imaging 
confirmed the vesicle morphology of the structures. Typical micrographs and schematic 
representation are shown in Figure 30. 
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Figure 249 A) Distribution plots, B) Decay times and C) Berry plots for 
triblock conjugates using multi-angle DLS and SLS 
 
Figure 30 TEM micrographs of vesicles self-assembled from PTMC50-b-
PVGLIG-b-PGA15 triblock conjugates with schematic representation for 
visualization showing PTMC50 (green), PVGLIG (red) and PGA15 (blue). 
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Degradation of the vesicle structure can be monitored by following the decrease in light 
scattering intensity as measured by light scattering. Tri-block vesicles were subjected to 
enzymatic degradation by MMP-2 over a 120 hour period with light scattering measurements 
taken every 24 hours. The observed decrease in scattering intensity was plotted in Figure 31. The 
vesicles showed slow but significant degradation, with scattered intensity decreasing to 60 %. 
The cancer-associated enzyme MMP-2 has been previously shown to be capable of cleaving a 
peptide substrate within a variety of nanostructure morphologies assembled from diblock 
conjugates, when the substrate is exposed on the particle surface
3
. In the case of these PTMC50-
b-PVGLIG-b-PGA15 vesicles the PVGLIG substrate links two polymer blocks, limiting its 
accessibility. In addition due to the vesicle morphology the PVGLIG peptide is present at both 
the exterior and interior surfaces of the structure; it is likely that the interior of the vesicle is 
inaccessible to MMP-2. As a result the degradation of the vesicles is slowed requiring longer 
time frame for cleavage of the substrate compared to structures of other morphology and 
composition.. To prove the selectivity of MMP-2 to the PVGLIG peptide PTMC30-b-PGA13 
vesicles were used as a negative control and show no degradation by MMP-2 over the same time 
frame. 
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Figure 251 Light scattering intensity was measured by DLS at 90 degrees of 
vesicles assembled from PTMC50-b-PVGLIG-b-PGA15 triblock conjugate as 
well as vesicles assembled from PTMC30-b-PGA13 as a control after 
incubation with MMP-2 active enzyme at 20 nM. 
 
Figure 32 DSC trace of PTMC50-b-PVGLIG-b-PGA15 bulk material showing 
a Tm of 40.5 °C and µDSC trace taken of a suspension of vesicles (100 mM) 
self-assembled from PTMC50-b-PVGLIG-b-PGA15 in water showing a Tm of 
35.5 °C. 
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The nanoprecipitation process is necessary for self-assembly of these structures due to the 
crystalline nature of the PTMC block. The crystalline nature of PTMC has previously been 
shown to play an important role in the self-assembly of a variety of stable structures
3,40,187
. This 
crystallinity is present in the bulk material and is maintained in the vesicle structure as evidenced 
by the melting temperature transition observed on a micro DSC trace seen in Figure 32. Above 
the melting temperature, the vesicle morphology is maintained, however, it is believed that some 
fluidization of the membrane occurs.  
The light scattering intensity of the vesicles at 90 degrees was monitored over a range of 
temperatures and the resulting data is show in Figure 33. A clear discontinuity is seen in the 
trend as the temperature approaches the Tm of the PTMC block. This change in the light 
scattering trend results from the fluidization of the PTMC membrane core. The intercept of the 
two linear regions correlates well with the transition observed in the µDSC curves. This change 
in scattering intensity likely results from changes in the refractive index of the PTMC membrane 
component. As the copolymer undergoes a transition at its melting point from semi-crystalline to 
amorphous, the apparent refractive index changes accordingly, resulting in a discontinuity in the 
observed scattering intensity. This change in scattered light intensity is indicative of a possible 
change in membrane structure. The effect of temperature on the membrane integrity is 
investigated in greater detail in the following chapter of this report. 
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Figure 33 Change in scattering intensity measured by DLS at 90 degrees of 
PTMC50-b-PVGLIG-b-PGA15 vesicles in water between 15 °C and 55 °C. 
  
Drug-Loading and Release of ImiHy from Vesicles 
Drug-loading with imipramine hydrochloride was achieved during the nanoprecipitation 
process with a feed weight ratio of 30 %. Due to electrostatic interactions between the positively 
charged drug and the negatively charged PGA15 block, encapsulation was done at pH 9.5, above 
the pKa of imipramine (8.9) to avoid precipitation of the system. The pH was reduced to 7.4 by 
successive rounds of ultrafiltration and dispersion. The final round of ultafiltration concentrated 
the loaded vesicles to a concentration of 5 mg/mL.  
 The imipramine was encapsulated into the vesicle with an encapsulation efficiency of 37 
%. This was determined by measuring the concentration of imipramine in the filtrate following 
purification and concentration of the loaded vesicles. Drug concentrations were determined by 
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UV/vis spectroscopy following the absorption band of IMI at 309 nm in the filtrate obtained 
(Figure 26). The release of IMI in vitro was subsequently studied under a variety of conditions, 
varying pH, temperature and under the presence of MMP-2. The release was measured by taking 
2 mL samples from the release medium and observing the absorbance peak of IMI by UV/Vis 
spectroscopy. In each case the removed volume was replaced in order to maintain sink 
conditions within the release media. The compiled release data is shown in Figure 34. Release 
studies showed that drug diffusion from the vesicles is sensitive to both pH and temperature; as 
well, drug release is enhanced in the presence of the tumor-associated enzyme MMP-2. 
The release of IMI from the tri-block vesicles was measured at 6 temperatures ranging 
from 15 °C to 55 °C. In all cases, the drug release rate increases with increasing temperature. 
Notably there is a significant discontinuity in release rate as the melting temperature of the 
PTMC block is approached. Release of IMI from the vesicles is relatively slow, increasing 
nominally with temperature in the lower three release temperatures (15, 22.5 and 26 °C). As the 
release temperature approaches the melting temperature of the PTMC block there is a sharp 
increase in the release rate. This is consistent with the postulated fluidization of the membrane, 
resulting in a marked increase in the diffusion of IMI from the vesicles. 
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Figure 34 Release of imipramine from PTMC50-b-PVGLIG-b-PGA15 vesicles 
under changing temperature and pH conditions as well as in the presence of 
MMP-2 active enzyme. 
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 Release of IMI was measured at room temperature in both neutral and low pH conditions 
(pH 4.5). There is a significant increase in release rate under low pH conditions, reflecting the 
pH-sensitivity of the PGA block. As the pH is reduced towards the pKa of the PGA block, 
electrostatic forces between the drug and PGA are reduced allowing for faster diffusion from the 
vesicles.  
 Finally, the vesicles showed significantly enhanced release in the presence of MMP-2 at 
38 °C. With no enzyme present, total release of the drug was achieved after approximately 16 
days. In the presence of 20 nM MMP-2, the same level of release was achieved within 4 days, 
with a nearly linear release profile. The release profiles with and without MMP-2 are similar 
during the initial 8 hours of measurements, however begin to diverge significantly by 12 and 
more so 24 hours, reflecting the slow cleavage of the PVGLIG block. In addition, as the peptide 
is cleaved, liberating the drug, we observe a change in the release profile to a more linear release 
rate compared to release not in the presence of MMP-2. 
  
Conclusions 
A triblock polymer-peptide conjugate consisting of a semi-crystalline synthetic polymer 
(PTMC), a pH-sensitive poly(amino acid) (PGA) and a biologically relevant peptide (PVGLIG) 
was successfully synthesized using thiol-ene coupling and organo-catalyzed ROP. Thiol-ene 
coupling between two macromolecules was achieved with efficiency by introducing a constant 
supply of the radical-producing initiator throughout the reaction mixture under constant UV 
exposure. Vesicles self-assembled from this system by a nanoprecipitation technique showed 
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significant changes in release of imipramine under varied conditions. Thermal, pH and enzyme 
sensitivities derived from the individual polymer, poly(amino acid) and peptide blocks, 
respectively, were observed in the final structures. Notably, vesicles show a significant increase 
in release rate under temperatures in excess of the melting temperature of PTMC50. The vesicles 
were cleavable in the presence of the tumor-associated enzyme MMP-2, and showed a 
corresponding enhanced release under these conditions. Such a multi-functional system 
comprised of multiple conjugated blocks represents a new step towards biomimetic systems and 
holds potential for further development into clinically relevant drug-delivery systems. 
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Chapter 5 Temperature-Induced Structural Changes in Hybrid Vesicles 
Introduction 
 Since their inception, self-assembled structures have gained considerable attention in a 
broad range of applications, due to their remarkable versatility
188
. Such structures have been 
produced from a variety of materials, including phospholipids, polymers, peptides and protein 
fragments
2,36,189
. Due to their likeness to natural biological systems, self-assembled systems have 
been of particular interest in biomedical applications.  
Self-assembled structures have been produced in a wide range of morphologies and 
derived from a wide range of amphiphiles
3,17,164
. Of particular interest have been vesicles formed 
from amiphiphilic block copolymers. Depending on the nature of the polymer blocks chosen, 
various morphologies can be achieved with unique properties such as “breathing”99, 
“schizophrenic”92 and can be produced to respond to a spectrum of stimuli58,66.  
Within the realm of vesicular systems, structures have been developed with a broad range 
of membrane permeability and stability. Efforts have been made to alter the membrane stability 
by the inclusion of cross-linking agents, allowing for stable vesicles with varying degrees of 
permeability related to the degree of crosslinking
66
. Polymer blends used to design vesicle 
systems have been shown to impact the elasticity of the membrane, and biodegradable 
membranes have had their rates of degradation improved by playing on the molecular weights 
and compositions of polymers used
134
. In addition, total disruption of the vesicular membrane 
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has been achieved with a wide range of stimuli-responsive materials
190
. Control over membrane 
integrity is pivotal in the move towards the design of cell-like structures. 
In liposomes, analogous to polymersomes, the phospholipid subunits exhibit a degree of 
crystallinity which can be exploited for temperature-sensitive drug-delivery
45
. The stimuli-
responsive character of liposomes occurs across the chain-melting transition (Tm) as the ordered 
character of the membrane is lost
67
. In such systems, this transition is exploited as drug release 
kinetics are more favourable above the Tm. Below the Tm, the hydrophobic chains exhibit a 
highly ordered state, which is lost above the Tm. 
67,68
  
In polymeric systems, the phenomenom of membrane crystallinity has been explored by 
Sanson et al, with the PTMC22-b-PGA14 system
45
. This polymersome structure showed the 
presence of crystalline character in larger vesicles directly related to the membrane integrity. In 
the case of PTMC, this transition was shown to be non-reversible due to the slow kinetics of 
recrystillization. The highly ordered chain packing in the crystalline state was not observable 
after heating beyond the chain-melting temperature. Other polymers, particularly, PEO have 
showed significant crystalline character in nanostructures
66
. Structures containing PEO have 
shown to exhibit significant morphological changes when heated past the chain-melting 
temperature. 
In both liposomes and polymersomes heating and cooling across the chain-melting 
temperature of crystalline regions of the membrane has resulted in significant rearrangement and 
morphological changes in self-assembled structures. The mechanisms of structural change are 
the occurance of both fusion and fission events. As structures are heated above the chain melting 
temperature crystalline regions undergo a micro phase separation and eventual budding and 
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ejection from the structure resulting in structural fission. The reverse mechanism has been 
observed for fusion events upon cooling of structures.  
 The synthetic polymer poly(trimethylene carbonate) (PTMC) has previously been 
demonstrated to form a wide range of self-assembled morphologies
3,4,113
. PTMC, due to its semi-
crystalline nature, can be assembled in a unique nanoprecipitation process to give rise to frozen 
structures, dependant on the crystallinity of the polymer. This crystalline nature has been shown 
to provide the structure with a temperature-sensitivity, resulting from the melting of PTMC 
within the structure
45
. Systems containing PTMC have been shown to produce temperature-
sensitive drug delivery systems as a result of their unique properties
89
. 
 In this study, we seek to probe the effect of temperature on the crystallinity and 
morphology of nanovesicles containing the hydrophobic polymer PTMC and the hydrophilic 
poly(amino acid) PGA. Stable vesicles from previous studies are subjected to consecutive rounds 
of heating and cooling and the observed changes in melting temperature and melting enthalpy are 
monitored. Vesicles are shown to fuse when heated above the melting temperature of the PTMC 
block and form larger stable vesicles.  
Experimental 
Materials 
The synthetic work to produce PTMC50-b-PVGLIG-b-PGA15 and the self-assembly of 
nanovesicles was described in detail in the previous chapter of this report. The empty (non-drug 
loaded) vesicles produced from that study were used in all experiments described here. 
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Thermal fusion of PTMC50-b-PVGLIG-b-PGA15 Vesicles 
Vesicles suspended in water were heated cycled through rounds of heating and cooling between 
60 °C and 10 °C with 120 min periods of equilibration at each extreme prior to analysis. Heating 
and cooling was done at a rate of 0.5 °C/min. Four cycles of heating and cooling were performed 
and samples were analyzed after each cycle.  
Dynamic light scattering (DLS) and static light scattering (SLS) 
DLS and SLS measurements were performed with a Brookhaven Laser Light Scattering system 
with a BI200SMv2 goniometer with a vertically polarized helium-neon diode laser at a 
wavelength of 636 nm and a BI-9000AT digital correlator with a 125 ns initial measurement 
time. Samples were kept at constant temperature (25 °C or 50 °C) for the duration of 
measurements. Measurements were taken every 10 ° between 60 ° and 140 °. SLS measurements 
were analyzed in a Berry plot to obtain the radius of gyration. 
Transmission electron microscopy (TEM) 
TEM images were recorded with a Philips CM10 TEM microscope using a 60 keV acceleration 
voltage. Samples were prepared by depositing one droplet of the dispersed nanoparticles onto a 
carbon-formvar grid (200 mesh coated with copper) and allowed to dry. No additional staining 
was performed. 
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Micro differential scanning calorimetry (µDSC) 
Thermograms were recorded using a VP-DSC MicorCalorimeter from MicroCal, LLC. 
Measurements were performed on 0.8 mL of 10 mM solutions of dispersed nanoparticles. 
Solutions were first stabilized at 10 °C prior to scanning. Measurements were taken between 10 
°C and 60 °C with a scan rate of 0.5 °C/min with 120 min isotherms at 10 °C and 60 °C.  
Temperature-Induced Structural Changes in Hybrid Vesicles  
 The PTMC50-b-PVGLIG-b-PGA15 hybrid vesicles are comprised of a synthetic, 
hydrophobic polymer PTMC, the poly(amino acid) PGA and the enzyme-sensitive enzyme 
PVGLIG. The PTMC50-b-PVGLIG-PGA15 self-assembled structures were made and well 
characterized as described in the previous chapter.  
 PTMC is a semi-crystalline polymer and has been well studied in the context of self-
assembly due to its ability to form a variety of highly stable nanostructures. The PTMC50-b-
PVGLIG-b-PGA15 bulk material has a melting temperature of 40.5 °C as seen in the DSC trace 
in Figure 33. The melting temperature is present in the self-assembled vesicles containing 
PTMC50, but the thermal transition has significantly broadened and the Tm shifted to a lower 
temperature. This shift arises from the curvature of the vesicles and the increased mobility or 
packing ability of the PTMC chains within the membrane. Although no direct quantitative 
measurements of membrane crystallinity have been performed it is believed that the decrease in 
melting temperature observed is a result of a lower degree of crystalinity in the membrane. 
 Previous studies have shown the size-dependence of the Tm in relation to the vesicle size, 
achieving a Tm equal to that of the bulk material at vesicle sizes of 5 um and higher
45
. This 
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results from the comparable degrees of crystallinity and lack of chain constraint in the larger 
vesicles. Reports from Sanson et al on vesicles from PTMC22-b-PGA14, showed no crystalline 
character in vesicles below 200 nm in diameter.  The vesicles used in this study are in the 200 
nm range, and still exhibit a melting temperature. The significantly higher molecular weight of 
the PTMC block as well as the presence of the PVGLIG peptide (with alternating amine and 
carbonyl groups capable of hydrogen bonding) may result in a decreased chain mobility and 
microphase separation of the PTMC50 block, favouring crystallization. An increased level of 
crystallization is also evidenced by the higher Tm (40.5 °C) observed, compared to the Tm 
reported by Sanson et al.  
Consecutive µDSC runs were performed between 10 °C and 60 °C with a heating and 
cooling rate of 0.5 °C/min and 2 hour equilibrations at both high and low temperatures. Peaks for 
Tm were observed in each run with the Tm increasing during each heating and cooling cycle. The 
observed heating curves are seen in Figure 35 and the obtained melting temperatures and melting 
enthalpies are summarized in table 3. 
Low molecular weight PTMC is known to crystallize slowly and within vesicle 
membranes confinement of the PTMC chains contributes to these slow kinetics. For this reason 2 
hour isotherms were performed at both the high and low temperature ranges of the µDSC runs. 
These isotherms may allow for closer association and ordering of the membrane chains and 
allow for recrystallization of the PTMC upon cooling. This method in addition to the large 
molecular weight of the PTMC block in the copolymer results in a recrystallization of the PTMC 
block within the nanostructures. Additionally, the presence of the PVGLIG peptide may 
contribute to a microphase separation and reduced mobility of the PTMC chains, favouring 
crystallization. 
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Table 4 Summary of melting temperatures and melting enthalpies of bulk 
homopolymer and the vesicle suspensions 
Heating cycle Tm (°C) Melting Enthalpy 
(J/mol) 
0 34.1 4.5 
2 36.0 4.8 
4 37.4 5.3 
Bulk 40.5 10.3 
 
 
Figure 35 DSC trace of bulk PTMC50-b-PVGLIG-b-PGA13 (left) and µDSC 
traces of vesicle suspensions in water over multiple rounds of heating. 
 
 With each cycle of heating and cooling, the melting temperature of the vesicles increases 
from a low of 34.1 °C of the originally produced vesicles to a high of 37.4 °C after 4 rounds of 
heating and cooling. This increase in melting temperature is suggestive of an increased stability 
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of the crystalline phase of the vesicles. In addition, the change in melting temperature is 
accompanied by an increase in the molar melting enthalpy of the vesicle suspension as well as a 
broadening of the melting range. As the vesicle melting stems from the degree of crystallinity of 
the PTMC block in the vesicle membrane, the increasing melting temperature and higher molar 
melting enthalpy suggests an increased heat capacity and an increased degree of crystallinity of 
the PTMC block after successive rounds of heating and cooling.  
 The vesicles prior, during and after 4 rounds of heating were analyzed by DLS and SLS. 
The full data set from this analysis can be seen in Figure 36 with the size data summarized in 
table 4. Vesicles prior to heating showed narrow size distributions over a range of angles with a 
linear q
2
 dependance of both the decay constants and (I
-1
)
-1/2
. These characteristics were also 
present in samples measured after 4 heating cycles. When light scattering measurements were 
taken of vesicle samples at 50 °C for the duration of the measurement, the distribution plots were 
noticeable broader suggesting the structures may no longer be monodispersed.  
 Prior to heating the vesicles had an RG of 86 nm and an RH of 94 nm resulting in an 
RG/RH value of 0.92, consistent with a vesicle morphology. Similarly, after several rounds of 
heating and cooling, the structures had an RG of 147 nm and an RH of 137 nm giving an RG/RH 
value of 1.07, once again consistent with vesicle morphology, suggesting that this morphology is 
stable throughout the heating process. There is however a significant size increase between the 
as-made vesicles and the structures after heating. This size increase is consistent with the 
observed increases in the melting temperature and the molar melting enthalpy. The origin of the 
size increase is attributed to the possible occurrence of fusion and/or fission events between 
vesicles and is discussed in greater detail below.The polymer chains within the larger vesicles 
109 
 
have less chain constraint and thus are able to achieve a higher degree of crystallinity within the 
structure.  
 DLS and SLS measurements were also taken of the vesicles after the 3
rd
 high temperature 
isotherm. The samples were maintained at 60 °C for the duration of the DLS and SLS 
measurements. When measurements were taken of the samples during heating we observed a 
broad size distribution with a mean RG of 188 nm and a mean RH of 77 nm, giving a RG/RH of 
2.4, suggestive of a non-vesicle morphology. This ratio likely results from the presence of 
multiple morphologies at high temperature. In this situation the presence of fusion and/or fission 
events give rise to a non-specific ratio.  While the vesicles structure is maintained before and 
after heating, there is a significant size increase with the vesicles passing through a transition 
state during the heating and cooling processes. Since the measurements were taken at high 
temperature while the PTMC chains were no longer in a crystallized state it is likely that these 
data represent an ill defined state. Due to the limitations of the DLS and SLS measurements it is 
difficult to draw conclusions from these data alone. 
 
Table 5 Summary of size data obtained from as made vesicles, vesicles under 
heating and after 4 cycles of heating. 
Sample RG (nm) RH (nm) RG/RH 
As made 86 94 0.92 
During 2
nd
 heating cycle 188 77 2.4 
After 4 heating rounds 147 137 1.07 
110 
 
 
Figure 36 Full DLS (distribution plots and decay constants) and SLS (Berry 
plots) data set obtained from triblock vesicles prior to heating (A), during 
heating (B) and after heating (C) 
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Figure 37 TEM micrographs of triblock nanostructures prior to heating 
(left), during the 3
rd
 heating (center) and after 4 heating and cooling cycles 
(right). 
  
In order to probe the morphological changes observed during the heating process, TEM 
images were taken of the nanostructures before, during and after heating. Typical micrographs 
from this examination can be seen in Figure 35. Before and after heating cycles, a vesicle 
morphology and size range consistent with the light scattering data can be seen. The images 
taken during the heating process appear to be a mix of structures with some intact vesicles of 
varying sizes clearly visible. There also appears to be fusion and/or fission of vesicles.  
 Fusion and fission events have frequently been observed in both liposomes and 
polymersomes. The fusion and fission events arise from a high level of defects in the vesicle 
membrane due to a mix of crystalline and non-crystalline regions resulting in microphase 
separation as the membrane approaches its chain-melting temperature. Fission generally occurs 
during heating when the domains created from phase separation are expelled from the 
membrane, resulting in an overall decrease in particle size. Fusion occurs by the reverse 
mechanism upon cooling of systems resulting in an overall increase in particle size. In addition 
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to the formation of defects during the gel-liquid-crystalline transition, fusion necessarily requires 
close proximity of particles, and fission can be strongly influenced by membrane curvature.  
 The overall increase in the vesicle sizes observed suggests that fusion is the dominant 
mechanism occurring. This process would occur during the cooling cycles. It is possible that due 
to the small size of the vesicles, the membrane curvature does not favour fission. The 
deformation observed on DLS/SLS and TEM during high temperature measurements results 
from these fusion and fission events, resulting in distorted particles and unclear sizes.  
 
Conclusions 
 Well defined monodispersed vesicles comprised of a triblock PTMC50-b-PVGLIG-b-
PGA15 system were shown to fuse when heated above the melting temperature of the structurally 
important, semi-crystalline PTMC50 block. The vesicles likely merge to form larger vesicles.. 
Vesicles produced with larger sizes show an increase in melting temperature and molar melting 
enthalpy towards that of the bulk material. This increase results from reduced chain constraint 
derived from the larger size, resulting in a higher degree of crystalline character in the 
membrane. These results help shed light on the important role that semi-crystalline polymers and 
PTMC in particular can play in the assembly and stability of nanostructures. This polymer may 
hold promise for producing nanostructures with temperature-tunable morphologies. By varying 
the chain length of PTMC and the duration of heating, it may be possible to produce a range of 
tunable nanostructures. 
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Chapter 6 Influence of Drug-Carrier Interactions on Encapsulation and 
Release 
Introduction 
In recent decades research in nanomedicine has had a particular focus on the 
encapsulation, controlled and triggered release of payloads
57,88,190
. In order to address this 
application a wide range of polymers, copolymers and nanoparticle morphology have been 
developed with varying degrees of success
3,113,128,183
. Research has largely focused on the design 
of unique nanoparticle carriers capable of transporting and releasing a payload under certain 
conditions and significant attention was devoted to the careful engineering of the carrier 
structure.  
An increasing number of drug delivery systems comprising varying morphologies that 
are loaded with a broad range of drugs have been successfully developed
147,149,191
. Notably, the 
drug loading capacity and drug release rates vary greatly between systems and drugs. Loading 
efficiencies approaching 70 % were achieved with DOX-loaded PTMC-b-PGA vesicles
89
, while 
others showed substantially lower loading capacities. Though efforts have been made to better 
understand the drug-carrier relationship, for many of these systems drug loading has not been 
studied in depth.. Such relationships and their impact on drug encapsulation and release should 
be a focus for the development of efficient drug delivery systems for a broad range of 
applications. 
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Significant work in this area has been done by the group of Kataoka
12,103,192
, who have 
showed the increase affinity for ionic micelles for payloads by increasing electrostatic 
interactions between the carrier and encapsulant. P(asp) was conjugated to PEG for production of 
polyionic micelles, having a highly charged character. Due to the charged nature of the micelle, 
oppositely charged drugs and payloads were shown to have a high affinity for the carrier through 
electrostatic interactions with the charged peptide block. Additionally, in aqueous solutions the 
charged enzyme lysozyme could become trapped in the micelles leading to the degradation of the 
structure. This affinity was further enhanced by addition of aromatic groups to the copolymer 
structure. In the case of this PEG-b-PAsp structure the presence of the charged peptide and the 
level of interaction between the peptide and the payload and enzyme were key to the structure 
function. 
PEG-SS-PAsp has been developed to not only enhance the solubility of the anticancer 
drug adriamycin,
106
 but additionally to provide a redox-sensitive release mechanism. Within the 
cytoplasmic environment the disulfide bridge linking the polymer and peptide could be 
selectively reduced by glutathione. Adriamycine showing strong interaction with the PAsp block 
through the electrostatics between the carboxyl unit of the peptide and the amine group of the 
drug. Such drug-carrier interactions are here greatly exploited for the benefit of the delivery 
system. 
Stimuli-responsive drug carriers have been of great interest due to their capacity to tailor 
the release conditions for each specific application
37,72,190
. In particular, pH-sensitive drug 
delivery systems have been the focus of numerous studies, and their sensitivity often stems from 
the presence of titratable charged groups present on the drug, carrier or both. By varying the pH, 
the degree of protonation can be impacted, which can alter the release kinetics of a drug
89,131
. 
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This type of electrostatically-controlled interaction between drug and carrier can be studied in 
depth by isothermal titration calorimetry (ITC). Additionally, this technique can be used to probe 
additional interactions and forces between host and guest such as hydrophobic interactions and 
van der Waals forces.  
 By studying the variety of interactions between drug molecules and potential carriers, 
delivery systems can be customized to maximize the drug-loading capacity and tailor the release 
kinetics under varying conditions. A more thorough understanding of how interaction between 
payload molecules and carriers affect loading and release may permit the customization of 
delivery systems for specific payloads that exhibit the best performance profiles.  
Thus, this study seeks to synthesize an amphiphilic copolymer based on the semi-
crystalline polymer PTMC and the poly(amino acid) PGA using the synthetic platform described 
in the previous chapters. This copolymer can be self-assembled into stable monodispersed 
vesicles. The loading and release of two model drugs (procaine hydrochloride and imipramine 
hydrochloride) were measured using drug-selective electrodes developed in-house. Using ITC 
the interactions between model drugs and copolymer carriers were studied with the aim of 
understanding how these forces impact the loading capacity and release kinetics of each of these 
drugs. 
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Experimental 
Materials 
Trimethylene carbonate (1,3-dioxane-2-one: TMC) was purchased from Boehringer Ingelheim 
and dried on magnesium sulfate in tetrahydrofuran (THF), sublimated and stored in a glove box 
prior to use. Allyl alcohol (99 %), 1,3-bis(2,6-diisopropylphenyl)-imidazol-2-ylidene (NHC, 97 
%), cysteamine (95 %), 2,2-dimethyloxy-2-phenylacetophenone (DMPA, 99 %) and imipramine 
hydrochloride (IMI, 99 %) were purchased from Sigma-Aldrich and used as received. γ-benzyl-l-
gluatmate N-carboxy anhydride (BLG-NCA) was obtained from Isochem France and used as 
received. Hydrobromic acid (Hbr, 33 wt %), was purchased from Acros Organics and used as 
received. Trifuoroacetic acid (TFA, 99.9 %) was purchased from Caledon Laboratory Chemicals. 
For synthesis dimethylformamide (DMF) and tetrahydrofuran (THF) were dried prior to use, all 
other solvents were used as received. 
Synthesis of ene-functionalized PTMC30 
Ene-functionalized PTMC30 was synthesized according to a previously described method. 
Briefly, recrystalized TMC was dissolved in dry THF (2 M) and added drop-wise to a solution of 
allyl alcohol (45 mM) and NHC (1 mM) in dry THF under inert atmosphere. The reaction was 
left stirring for 90 min at room temperature and quenched with methanol. PTMC30 was 
precipitated in ice-cold methanol and purified by centrifugation. The degree of polymerization 
was measured by end-group analysis of 
1
H NMR spectrum. PTMC30 was produced with a 
polydispersity of 1.13 at a yield of 85 %. 
1
H NMR (CDCl3, 400 Hz) δ(ppm)= 2.0 
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(C(O)OCH2CH2CH2OC(O)), 4.2 (C(O)OCH2CH2CH2OC(O)), 4.59 (H2C=CH-CH2-), 5.29 
(H2C=CH-CH2-), 5.89 (H2C=CH-CH2-). 
Amine-functionalization of PTMC30 by thiol-ene coupling 
Ene-functionalized PTMC30 (1 eq), Cysteamine (3 eq) and DMPA (3 eq) were dissolved in DMF 
and irradiated with UV light for 15 min. The NH2-PTMC was then precipitated in cold methanol, 
centrifuged and dried under vacuum. Successful functionalization was confirmed by analysis of 
1
H NMR spectrum of the dried product. Polydispersity index was experimentally determined by 
gel permeation chromatography (GPC). 
1
H NMR (CDCl3, 400 Hz) δ(ppm)= 2.0 
(C(O)OCH2CH2CH2OC(O)), 2.55 (CH2SCH2CH2NH2), 2.75 (CH2SCH2CH2NH2), 3.02 
(CH2SCH2CH2NH2) 4.2 (C(O)OCH2CH2CH2OC(O)), 4.23 (H2C=CH-CH2). 
Polymerization of BLG-NCA from PTMC30-NH2 macroinitiator 
PBLG was grown from the amine terminus of PTMC30 via ROP using the PTMC30-NH2 as a 
macroinitiator. In a glove box under inert conditions BLG-NCA and PTMC30-NH2 were 
dissolved in dry DMF with [BLG-NCA]:[PTMC30-NH2] = 14, and left stirring for 48 h. The 
solution was removed from the glove box and PTMC30-b-PBLG13 was precipitated in diethyl 
ether. The precipitate was removed by centrifugation and washed repeatedly with diethyl ether. 
1
H NMR (DMSO, 400 Hz) δ= 7.18 (d) 5H, C(O)CH[(CH2)2C(O)OCH2Ph]; δ= 5.09 (m) 2H, 
C(O)CH[(CH2)2C(O)OCH2Ph]; δ= 4.41 (m) 1H, C(O)CH[(CH2)2C(O)OCH2Ph]; δ=2.45 (m) 2H, 
C(O)CH[(CH2CH2)C(O)OCH2Ph]; δ=1.95 (m) 2H, C(O)CH[(CH2CH2)C(O)OCH2Ph]. 
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Acid hydrolysis of PTMC30-b-PBLG13 to PTMC30-b-PGA13 
The benzyl side chain of PTMC30-b-PBLG13 was cleaved by acid hydrolysis to produce 
PTMC30-b-PGA13. In a typical cleavage PTMC30-b-PBLG13 was dissolved in TFA and HBr and 
left stirring for 2 h. PTMC30-b-PGA13 was precipitated in diethyl either and isolated by filtration. 
The product was dissolved in water and purified by dialysis against water for 2 days with 
frequent water changes. The final PTMC30-b-PGA13 product was freeze dried to produce a white 
powder. 
1
H NMR (DMSO, 400 Hz) δ= 4.41 (m) 1H, C(O)CH[(CH2)2C(O)OH]; δ=2.45 (m) 2H, 
C(O)CH[(CH2CH2)C(O)OH]; δ=1.95 (m) 2H, C(O)CH[(CH2CH2)C(O)OH]. 
Vesicle self-assembly and drug encapsulation by nanoprecipitation 
Self-assembly of imipramine-loaded and procaine-loaded vesicles from PTMC30-b-PGA13 was 
performed via a previously reported nanoprecipitation method. PTMC30-b-PGA13 (10 mg) and 
imipramine hydrochloride or procaine hydrochloride (40 % feed weight ratio) were dissolved in 
DMSO (500 µL). With vigorous stirring, buffer (4.5 mL) pH = 9.5 (for IMI) or pH 7.4 (for 
PrHy) was added over 15 s. The unbound drug in the IMI-loaded nanoparticle suspension was 
removed by dialysis against buffer pH 7.4 over 30 min (MWCO = 13 000), with one buffer 
change. The vesicle suspension mixtures were purified by 3 rounds of ultrafiltation (pore size 25 
nm) and the dispersion volume was reduced to 2 mL (5 mg/mL). The structural morphology was 
probed with dynamic and static light scattering and TEM and the drug loading was measured by 
drug-selective electrodes. 
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Drug release measurements 
Aliquots of drug-loaded vesicles were dispersed in 50 mL of buffer (pH 7.4 or 4.5) with gentle 
stirring and drug concentrations were monitored by drug-selective electrodes over a 36 hour 
period under ambient conditions. Readings of drug concentrations were taken every 10 seconds. 
Preparation of drug-selective electrodes 
A drug-ion complex was first prepared. Poly(vinyl chloride) (PVC) (0.5 g) was dissolved 
in THF (30 mL). Separately, procaine hydrochloride (0.955 g for PrHy membrane) or 
imipramine hydrochloride (1.109 g, for IMI membrane) was dissolved in a 1:9 THF:H2O mixture 
(100 mL). The dissolved PVC was then added drop-wise to the drug solution with vigorous 
stirring and left for 48 h to complex. The complex was then precipitated in cold deionized water 
and filtered by vacuum filtration. The filtrate was washed several times with deonized water and 
dried overnight in a vacuum oven. 
The prepared complex was used in the preparation of ion-selective membranes. Drug-on 
complex (either PrHy-PVC or IMI-PVC) was dissolved in THF (15 mL) and the polymeric 
plasticizer poly(ethylene-co-vinyl acetate-co-carbon monoxide) (PE-co-PVA-co-CO) and 
NaTPB were dissolved separately in THF (15 mL). The two solutions were mixed and allowed to 
stir for 10 min. The mixture was then poured into a Petri dish (55 mm diameter) and the solvent 
was allowed to evaporate over 2 – 3 days. The membrane was then carefully removed from the 
Petri dish and stored. The selectivity of the membrane is attributed to the presence of the drug 
ion within the membrane.  
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The drug membrane was cut-out into a disc and adhered onto the end cap of the electrode 
body using THF which was placed on the flat concentric surface of the tip.  Leakages of the tip 
with drug membrane were tested by filling the tip with distilled de-ionized water after the THF 
had been evaporated. After checks for leakages, the end cap with drug membrane was dried and 
stored in a desiccator and kept from light. Prior to use, the membrane was soaked in a 0.01 M 
PrHy solution (PrHy membrane) or 0.01 M IMI solution (IMI membrane) for half an hour. 
Calibration of PrHy and IMI selective probes was conducted over a concentration range of 10
-5
 – 
10
-1
 M. Stability of the electrode response was measured at 10
-3
 M of either PrHy or IMI over a 
24 h period. Calibration and stability testing can be seen in Figures 38and 39. 
 Prior to all measurements with the designed drug-selective electrodes, both calibrations 
and long-term stability testing was performed. Calibration was done over a range of 10
-5
 – 10-2 
M PrHy (or IMI), and long-term stability testing was conducted over a 24 h period. The results 
of both of these tests are given below in Figures 38 and 39. 
 
Figure 38 Long-term stability (right) and calibration curve (left) of PrHy-
selective electrode 
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Figure 39 Long-term stability (left) and calibration curve (right) of IMI-
selective electrode 
 PrHy selective electrode was shown to display a linear response within the range of 10
-5
-
10
-2
 M with an average drift of 0.1 mV/h. Likewise the IMI-selective electrode showed a linear 
response between 10
-5
 – 10-2 M with an average drift of 0.3 mV/h over a 16 h period. For the 
purposes of this project both electrodes are usable within the concentration and time ranges of 
the planned experiments. 
Size-exclusion chromatography 
All SEC measurements were performed in dimethylformamide (DMF) with LiBr (1 g/L) as the 
eluent. The flow rate was fixed at 0.8 mL/min. Two 7.5 mm x 300 mm PLgel, 5 µm Mixed-D 
columns (Polymer Laboratories) were coupled to a guard column, 7.5 mm x 50 mm, PLgel, 5 µm 
(Polymer Laboratories). The system was equipped with a differential refractive index (RI) 
detector. Calibration was performed with polystyrene standards. 
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1
H NMR 
All measurements were conducted using a Brukner Adsvance spectrometer operating at 400 
MHz at room temperature with a fixed (7.5 s) relaxation time. d-DMSO or CDCl3 was used as a 
reference signal (δ=2.5 ppm and 7.4 respectively). 
Dynamic light scattering (DLS) and static light scattering (SLS) 
DLS and SLS measurements were performed with a Brookhaven Laser Light Scattering system 
with a BI200SMv2 goniometer with a vertically polarized helium-neon diode laser at a 
wavelength of 636 nm and a BI-9000AT digital correlator with a 125 ns initial measurement 
time. Samples were kept at constant temperature (25 °C) for the duration of measurements. 
Measurements were taken every 10 ° between 60 ° and 140 °. SLS measurements were analyzed 
in a Berry plot to obtain the radius of gyration. 
Transmission electron microscopy (TEM) 
TEM images were recorded with a Philips CM10 TEM microscope using a 60 keV acceleration 
voltage. Samples were prepared by depositing one droplet of the dispersed nanoparticles onto a 
carbon-formvar grid (200 mesh coated with copper) and allowed to dry. No additional staining 
was performed. 
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Isothermal titration calorimetry (ITC) 
The calorimetric data on the binding interactions between procaine hydrochloride, imipramine 
hydrochloride and the copolymer PTMC30-b-PGA13 were obtained using a Microcal VP-ITC 
calorimeter (Northampton, MA). The stock solutions of 10 mM of drug were selected for 
titration onto 1 mM solution of vesicles. The volume of individual injections varied for each run 
increasing from a starting volume of 2 µL to a final volume of 20 µL until the total volume was 
injected and/or saturation was observed. All titrations were conducted at 25.0 °C, with delays 
between injections varying until a return to the baseline was achieved, generally 200 seconds 
was sufficient. The microcalorimeter consists of a reference cell and a sample cell of 
approximately 1.4 mL in volume, and the drug solution was injected from a filled 281.72 μL 
injection syringe into the sample cell filled with the copolymer solutions. The syringe is tailor-
made such that the tip acts as a blade-type stirrer to ensure an efficient mixing at 307 rpm. In this 
study, we utilized identical injection protocol and same time interval between successive 
injections for all ITC measurements.  
Synthesis of PTMC30-b-PGA13 
The synthesis of PTMC30-b-PGA13 was achieved using a combination of organocatalyzed 
ROP and thiol-ene coupling. The full synthetic strategy is shown in Scheme 3. Ene-
functionalized PTMC30 was synthesized using an organic catalyst as described in previous 
chapters, followed by amine-functionalizations by UV-initiated thiol-ene coupling. The reaction 
was completed within 10 minutes of exposure to UV light with near total functionalization. The 
functionalization was monitored by the disappearance of 2 peaks associated with the ene-
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functionality on the 
1H NMR spectrum at δ = 5.32 and 5.81 ppm and the subsequent appearance 
of small triplets between 2.5 and 3 ppm associated with the addition of cyateamine to the 
PTMC30. These peaks are visible on the 
1
H NMR spectra seen in Figure 40. 
 
Scheme 3 Synthetic strategy for PTMC30-b-PGA13 
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Amine-functionalized PTMC30 was used as a macroinitiator for the ring-opening 
polymerization of BLG-NCA. The reaction proceeded to completion after 48 hours and was 
purified by precipitation to give PTMC30-b-PBLG13. The appearance of signals from the PBLG 
on the 
1
H NMR spectrum are indicative of the successful polymerization and the degree of 
polymerization was confirmed by integration of the 
1
H NMR signals. A degree of polymerization 
of 13 was specifically targeted with the goal of producing a final copolymer with a hydrophilic 
weight fraction (f) of 36 %. This value of f was chosen with the intent to produce nanoparticles 
with a vesicular morphology. In a second step the benzyl pendant group of the PBLG block was 
cleaved from the copolymer by acid hydrolysis in TFA/HBr. The cleavage was confirmed by the 
disappearance of the benzyl peaks from the 
1
H NMR of the copolymer. The final PTMC30-b-
PGA13 copolymer was dried under vacuum. 
Self-Assembly and Drug Loading of Vesicles from PTMC30-b-PGA13 
Following the self-assembly by nanoprecipitation and purification, the resulting 
nanostructures were analyzed by DLS, SLS and TEM. Light scattering analysis showed narrow 
size distributions over a range of angles, a linear q
2
 dependence of the decay rate (Γ). 
Additionally, the Berry plot showed a linear relationship between (I
-1
)
-1/2
 and q
2
. These 
relationships can be clearly seen in Figure 41. 
DLS analysis revealed a RH value of 77 nm and SLS produced a RG value of 81.2 nm 
giving a RG/RH value of 1.05, consistent with the expected vesicle morphology. The structures 
were stable and well-defined. Light scattering analysis was followed by visual inspection by 
TEM. Typical micrographs are given below in Figure 42 with a schematic representation of the 
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structure for visualization. The micrographs revealed uniform vesicle structures consistent with 
the light scattering analysis.  
 
 
Figure 40 
1
H NMR spectra (from top to bottom) of ene-PTMC30, PTMC30-
NH2, PTMC30-b-PBLG13 and PTMC30-b-PGA13 after purification at each 
step, showing the step-wise synthesis of the final conjugate 
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Figure 41 Full DLS and SLS data set showing q
2
 dependence of the decay 
time (left), narrow and well defined distribution over multiple angles (center) 
and linear progression of (I
-1
)-
1/2
 and q
2
 (right) 
 
Figure 42 TEM micrographs of PTMC30-b-PGA13 vesicles with schematic 
representation showing PTMC30 (green) and PGA13 (blue). 
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Encapsulation of the model drugs procaine hydrochloride and imipramine hydrochloride 
was achieved via co-precipitation during the self-assembly process. The amount of drug 
encapsulated was measured by performing ultrafiltration on the particle suspension and 
measuring the residual drug content in the filtrate. Procaine was encapsulated at 24 % while 
imipramine showed 37 % encapsulations and the explanation for the observed difference will be 
discussed below. 
Study of Drug-Carrier Interactions 
In order to evaluate the impact of drug-carrier interactions on the encapsulation efficiency 
and release kinetics of this system, two model drugs were chosen for evaluation; procaine 
hydrochloride (PrHy) and imipramine hydrochloride (IMI). The chemical structure of both drugs 
is given in Figure 43. Both drugs are amphiphilic and possess surfactant-like characteristics, 
though the hydrophobic region of procaine is less significant than that of imipramine. 
Additionally, though both drugs have a titratable tertiary amine, the charge on the tertiary amine 
in the procaine structure is considerably shielded by the surrounding ethyl groups. This effect is 
not present with imipramine. The similarities and difference in the structure of the two drugs 
makes them ideal models to compare the effects of drug-carrier interactions.  
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Figure 43 Chemical structure of model drugs PrHy (left) and IMI (right) 
 
In order to measure the magnitude and characteristics of interaction between the two 
model drugs and the PTMC30-b-PGA13 copolymer vesicles, the drugs were titrated into a 
dispersion of the copolymer vesicles by ITC at pH 7.4, 9.5 and 4.5.  
At pH 7.4, heat changes recorded from the titration of procaine were small relative to the 
much larger heat changes observed from the titration of imipramine under similar conditions. 
The raw data from this titration is shown in Figure 44. Additionally, when the enthalpy values 
were extracted and plotted (Figure 44), the titration of imipramine revealed a significant heat 
transition resulting in saturation of all interaction sites and the curve could be fitted to a two-site 
interaction model, where it was dominated by the electrostatic interaction. The interaction 
models were established by the ITC software and involved selecting the number of sites and 
varying the thermodynamic parameters over a sequence of iterations, until an appropriate fit was 
achieved. In the case of imipramine, this was consistent with the expected strong electrostatic 
interactions between the positively charged amine group on the drug and the negatively charged 
carboxyl group on the copolymer. In contrast, the titration of procaine hydrochloride showed no 
major transitions and the data could be fitted to a one-site interaction model. Due to the structure 
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of PrHy we concluded that the minimal interaction was attributed to shielded charge and the 
significantly reduced hydrophobic group relative to IMI.  
  
 
Figure 44 Full ITC data set obtained at pH 7.4 showing raw heat curves from 
titration of PrHy (top left) and IMI (top right) with corresponding enthalpy 
curves below fitted to interaction site models. 
The minimal interaction observed may be responsible for the comparably lower 
encapsulation efficiency observed with this system.  It is worth noting that due to the dominant 
electrostatic interaction observed with imipramine encapsulation at pH 7.4, the complexes 
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formed precipitated from solution. Hence, encapsulation of imipramine was performed at pH 9.5 
(above the pKa of both drugs), however the relative importance of drug-polymer interaction is 
similar at high pH. 
Titrations of the two model drugs were performed at pH 9.5 and the raw data and 
enthalpy curves are shown in Figure 45. At pH 9.5, the titration of procaine again exhibited 
minimal interaction that is consistent with weak electrostatic interaction and very weak 
hydrophobic interaction. Imipramine, with a pKa of 8.9, showed significantly reduced interaction 
at pH 9.5 than at pH 7.4due to the protonation of the drug that eliminated the positive charges 
resulting in the removal of electrostatic interaction previously present. The enthalpy curve did 
show a significant transition and could be fitted to a one-site interaction model, that was 
consistent with hydrophobic interaction forces expected to be present at high pH. This interaction 
at high pH is responsible for the higher encapsulation efficiency when compared to PrHy. 
Finally, titrations of both drugs were performed at pH 4.5, approaching the pKa of the 
PGA block of the copolymer (4.3). The low pH titrations are similar in interaction to the high pH 
case and the data set can be seen in Figure 46. 
The titration of procaine at low pH again showed minimal interactions with no significant 
transitions observed in the enthalpy plot. In contrast the titration of imipramine at low pH, 
significant heat changes with a transition on the enthalpy curve was observed and the data could 
be fitted to a one-site interaction model. This correlated well with the expected minimal 
electrostatic interactions and the dominating hydrophobic interactions. 
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Figure 45 Full ITC data set obtained at pH 9.5 showing raw heat curves from 
titration of PrHy (top left) and IMI (top right) with corresponding enthalpy 
curves below fitted to interaction site models. 
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Figure 46 Full ITC data set obtained at pH 4.5 showing raw heat curves from 
titration of PrHy (top left) and IMI (top right) with corresponding enthalpy 
curves below fitted to interaction site models. 
 At all pHs the interaction of imipramine with the copolymer was significantly higher than 
that of procaine. The weakest interactions observed between imipramine and the copolymer were 
at pH 9.5 and were nonetheless stronger than the interactions between procaine and the 
copolymer at all pHs. This difference in the magnitude of interaction has a significant impact on 
the encapsulation efficiency of the drugs within the polymer vesicles. Procaine was encapsulated 
at 24 % efficiency while imipramine showed 38 % encapsulation, an increase in encapsulation of 
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50 %. Due to the hydrophilic nature of procaine, it is believed that the drug is encapsulated into 
the aqueous hydrophilic cavity of the vesicle. In contrast, since the encapsulation of imipramine 
was performed at high pH (above the pKa of the drug), where the drug was uncharged and 
largely hydrophobic, it was likely that the drug molecules were encapsulated within the 
hydrophobic region of the vesicle membrane. This type of encapsulation has been previously 
observed with similar systems. 
  
In Vitro Drug Release of Procaine Hydrochloride and Imipramine Hydrochloride 
 The in vitro release of PrHy from the vesicles was measured at pH 7.4 using a PrHy-
selective electrode. The release profile obtained is shown in Figure 47. The release of procaine 
from the vesicles was quite rapid showing 50 % release after only 30 min and nearly 85 % drug 
release within 5 hours. As there is little interaction between the drug and vesicles (as evidenced 
by ITC measurements) there is no strong driving force holding the drug in the vesicles. The 
release of the drug molecules occurs by simple diffusion of the drug across the vesicle membrane 
driven by the concentration gradient driving force. With no strong drug-polymer interaction, the 
drug diffuses against the concentration gradients with relative ease.  
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Figure 267 Release of procaine hydrochloride from PTMC30-b-PGA13 vesicles 
 
The release of IMI was measured at pH 7.4 and 4.5 using an IMI-selective electrode. The 
results are shown in Figure 48. At pH 7.4 the release of IMI was quite slow compared to that of 
PrHy, showing a 50 % release after approximately 11 h and 70 % release after 24 hours. It is 
believed that the much slower release of IMI from the vesicles compared to that of procaine 
resulted from the much stronger interactions present between IMI and the vesicles compared to 
PrHy and the vesicles as evidenced by ITC measurements. The strong electrostatic interactions 
between the positively charged drug and the negatively charged internal and external surfaces of 
the vesicles traps the drug within vesicles (either membrane or cavity) reduced the release and 
diffusion of the drug molecules from the vesicle to the bulk solution. 
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Figure 48 Release of imipramine hydrochloride from PTMC30-b-PGA13 
Vesicles 
 
The differences in the release rates between PrHy and IMI correlated very well to the 
magnitude of interaction between the drugs and the vesicles determined from ITC measurements 
at pH 7.4. It is believed that drug-polymer interaction plays a key role in the encapsulation and 
release of drugs from delivery systems and this can be used to select appropriate drug carriers for 
the encapsulation and delivery of drug molecules. Further studies are needed to confirm this 
hypothesis.  
 The release of IMI at pH 4.5, which is close to the pKa of the PGA shell (4.3) of the 
vesicles, was faster than the release at pH 7.4, showing 50 % release after only 2.5 hours and 75 
% release after 10 hours. As described above, the release is largely influenced by the drug-
polymer interactions which are predominately hydrophobic at low pH and electrostatic at neutral 
pH. These interactions are governed by the pH conditions. As the pH of the release media 
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approaches the pKa of the PGA shell (4.3), the PGA becomes protonated, neutralizing the 
negative surface charges. The electrostatic interactions between the positive drug and the 
negative polymer which previously trapped the drug within the vesicles are no longer present (or 
greatly reduced) allowing for more rapid drug release. 
 Kataoka et al have previously described a system comprised of PEG-b-PAsp in which the 
affinity of the system towards a drug and a relevant enzyme was significantly enhanced upon 
modification.
12,103
 Firstly, the addition of aromatic groups to the structure enhanced affinity with 
the target enzyme, and addition of charged components to the copolymer backbone enhanced the 
ionic nature to the polymer and directly resulted in a greater affinity between the carrier and the 
drug.  The results presented here are consistent with the general theme of Kataoka’s work. In all 
cases affinity of the drug to the carrier seems to directly correlate to enhanced encapsulation 
efficiency and enhanced affinity for the drug and other charged species.  
 Although, the localization of the two drugs used in this study may vary (vesicle core vs 
vesicle membrane), the general trend relating encapsulation and release rate with the magnitude 
of interaction between the carrier and drug can be very valuable to the drug delivery community. 
This is internded as a preliminary study to give insight into the effects of drug-carrier 
interactions on encapsulation and release to encourage the design of appropriate carriers for 
specific drugs.  
 This work provides some insight however, a more comprehensive study should be done 
in order to compare multiple drugs over a broader array of interaction conditions. In this fashion 
a more in-depth understanding of release mechanisms and how they relate to interactions 
between drugs and carriers can be achieved.  
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Conclusions 
PTMC30-b-PGA13 was synthesized by a combination of organo-catalyzed ROP and rapid 
UV-initiated thiol-ene coupling with high yield. Well-defined mono-dispersed vesicles can be 
prepared from the copolymer via a nanoprecipitation technique and both procaine hydrochloride 
and imipramine hydrochloride can be loaded into the vesicles with high efficiency. Interactions 
of the two model drug with the copolymer were probed by ITC and the data correlated with 
encapsulation efficiency and drug release rates. Both drugs showed total drug release within 36 
hours, with procaine releasing within 5 hours resulting from low interaction of the drug with the 
carrier. Additionally, the reduction of electrostatic forces at low pH was correlated with 
enhanced drug release of imipramine from the vesicle carrier. These results point to the inherent 
need to understand the interaction between drugs and potential carriers in order to tailor the 
system to high loading efficiency and optimal release rates. ITC has proven to be an invaluable 
tool to probe this phenomenon and it can be used to select and match drugs with optimal carrier 
systems. 
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Chapter 7 Conclusions and Recommendations 
In this work a synthetic polymer (PTMC) was combined with a biologically-relevant 
peptide (PVGLIG) and a poly(amino acid) (PGA) to produce diblock and triblock copolymers 
capable of self-assembly into a range of well-characterized particle morphologies (Chapters 3 & 
4). Then influence of both temperature and pH on drug release was studied with significant 
stimuli-responsive behaviour observed. Structures containing PVGLIG were subjected to 
enzymatic degradation by the tumor-associated enzyme MMP-2 and demonstrated selective-
degradation in biologically-relevant conditions.  
The membrane integrity and occurrence of fission and fusion events was investigated by 
heating and cooling hybrid vesicles across the chain-melting temperature (Chapter 5). Special 
attention is paid to discrepancies observed relative to comparable vesicular systems in the 
literature.  
Finally, the work aimed to understand the relationship between drug-carrier interactions 
and the encapsulation and release of drugs from polymer vesicles (Chapter 6). The interactions 
between two model drugs and PTMC30-b-PTMC13 vesicles were probed using ITC, and the 
encapsulation efficiency and drug release of these drugs was monitored using drug-selective 
electrodes. The observed interactions were correlated with the release rates and encapsulation 
capacities. In highly charged systems the drug release rate is largely governed by electrostatic 
interactions. The following conclusions can be drawn from this work. 
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General Contributions 
PTMCn-b-PVGLIG diblock nanostructures 
 A combination of organo-catalyzed ring-opening polymerization, peptide synthesis and 
thiol-ene click chemistry was used to successfully access various structurally well-defined 
polymer-peptide hybrids comprised of PTMC and the MMP-2 peptide substrate PVGLIG. 
Synthesis of ene-functionalized PTMC by use of an N-heterocyclic carbene catalyst and 
functionalized alcohol initiator had not previously been reported and offers a facile strategy for 
production of PTMC with other functionalities. Click chemistry was used to successfully couple 
the as-made PVGLIG peptide to varying block length PTMC featuring a terminal ene functional 
group to form the PTMCn-b-PVGLIG hybrids. The amphiphilic nature of the di-block system 
allows for the self-assembly of PTMCn-b-PVGLIG by nanoprecipitation yielding stable 
monodispersed structures of varying morphology. The observed morphologies were not 
consistent with traditional structural morphologies based on the hydrophobic/hydrophilic 
balance. This discrepancy stems from the presence of the semi-crystalline PTMC block and the 
nanoprecipitation process used for self-assembly, which can freeze the structure morphology 
outside of thermodynamic equilibrium.  
With the enzyme-cleavable peptide as a structural element in the hybrids, these particles 
are selectively degradable by the tumor-associated enzyme MMP-2. Significant disruption of all 
structure morphologies was observed after incubation with MMP-2 over a 48 h period. These 
MMP-sensitive structures represent the first step towards a targeted drug delivery system for the 
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tumor microenvironment. The unique morphologies provide valuable insight into the mechanism 
of self-assembly of complex polymer-peptide hybrid molecules. 
 
PTMC50-b-PVGLIG-b-PGA15 multi-functional vesicles 
The unique synthetic strategy used for synthesis of diblock hybrid conjugates was here 
expanded to produce a triblock system consisting of PTMC, a pH-sensitive poly(amino acid) 
(PGA) and a biologically relevant peptide (PVGLIG). Thiol-ene coupling between two 
macromolecules was achieved with efficiency by introducing a constant supply of the radical-
producing initiator throughout the reaction mixture under constant UV exposure. Vesicle self-
assembled from this system by a nanoprecipitation technique showed significant changes in 
release of imipramine under varied conditions. Thermal, pH and enzyme sensitivities derived 
from the individual polymer, poly(amino acid) and peptide blocks, respectively, were observed 
in the final structures. Notably, vesicles show a significant increase in release rate under higher 
temperatures in excess of the melting temperature of PTMC50. Additionally, drug-release could 
be enhanced under low pH conditions. The vesicles were cleavable in the presence of the tumor-
associated enzyme MMP-2, and showed a corresponding enhanced release under these 
conditions. Very few systems have been reported in literature in which an enzyme-specific 
peptide is used as a linker within the structure of a polymersome. In this respect the structures 
produced in this work are unique. Such a multi-functional system comprised of multiple 
conjugated blocks represents a new step towards biomimetic systems and holds potential for 
further development into clinically relevant drug-delivery systems. 
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Thermally-induced structural changes in hybrid vesicles 
 Well defined monodispersed vesicles comprised of a triblock PTMC50-b-PVGLIG-b-
PGA15 system were shown to fuse when heated above the melting temperature of the structurally 
important, semi-crystalline PTMC50 block. The vesicles likely merge to form larger vesicles. The 
observed crystalline behaviour in these small vesicles is in contrast to previous reports by Sanson 
et al which demonstrate that structures below 200 nm in size showed no crystalline behaviour. 
The difference seen in this system is likely due to the presence of the PVGLIG peptide and the 
increase size of the PTMC block. These two factors may contribute to a microphase separation of 
crystalline and gel regions as temperatures approach the chain-melting temperature of the 
copolymer. Vesicles produced with larger sizes show an increase in melting temperature and 
molar melting enthalpy towards that of the bulk material. This increase results from reduced 
chain constraint derived from the larger size, resulting in a higher degree of crystalline character 
in the membrane.  
Unlike previously reported systems, after melting of the membrane, the crystalline 
character was reversible with Tm being observed in consecutive DSC scans. Compared to 
previously published literature the equilibrations performed at both high and low extremes of 
heating and cooling cycles likely allow sufficient time for the slow recrystallization of PTMC 
within the vesicle membrane. In addition, the presence of PVGLIG and the larger molecular 
weight of PTMC likely contribute to the crystalline character of the vesicles. These results help 
shed light on the important role semi-crystalline polymers in general and PTMC in particular can 
play in the assembly and stability of nanostructures. This polymer may hold promise for 
producing nanostructures with temperature-tunable morphologies. By varying the chain length of 
143 
 
PTMC and the duration of heating, it may be possible to produce a range of tunable 
nanostructures. 
 
Drug-carrier interaction and the implications for encapsulation and release 
 The synthetic strategy employed in the previous chapters to generate diblock and 
triblock hybrid conjugates was modified here to produce a copolymer from PTMC and the 
poly(amino acid) PGA. PTMC30-b-PGA13 was synthesized by a combination of organocatalyzed 
ROP and rapid UV-initiated thiol-ene coupling with high yield. Well-defined mono-dispersed 
vesicles can be prepared from the copolymer via a nanoprecipitation technique and both procaine 
hydrochloride and imipramine hydrochloride can be loaded into the vesicles with high 
efficiency. Interactions of the two model drug with the copolymer were probed by ITC and the 
data correlated with encapsulation efficiency and drug release rates. Both drugs showed total 
drug release within 36 hours, with procaine releasing within 5 hours resulting from low 
interaction of the drug with the carrier. Additionally, the reduction of electrostatic forces at low 
pH was correlated with enhanced drug release of imipramine from the vesicle carrier. The 
electrostatic character of both the nano-vesicles and the model drugs was shown to have a 
significant impact on both drug encapsulation and release. These results point to the inherent 
need to understand the interaction between drugs and potential carriers in order to tailor the 
system to high loading efficiency and optimal release rates. ITC has proven to be an invaluable 
tool to probe this phenomenon and it can be used to select and match drugs with optimal carrier 
systems. 
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Recommendations for Future Work 
 Based on the results of the research presented above, the impact of the crystalline nature 
of copolymers should be further investigated in the context of both self-assembly and 
temperature-induced morphology changes. Additionally, the potential for the produced enzyme-
cleavable systems for use as drug delivery systems should be further pursued. In addition, a more 
comprehensive look at a broader range of drug-carrier combinations should be done to better 
understand the role of differing interactions on the efficacy of drug delivery systems. The 
following recommendations are proposed. 
 
The role of PTMC and semi-crystalline polymers in self-assembly 
 The PTMCn-b-PVGLIG diblock structure synthesized in this work were capable of 
forming nanostructure morphologies inconsistent with what would be classically expected based 
on their hydrophilic weight fraction. This phenomenon has been attributed to the presence of the 
semi-crystalline PTMC block in the structures and the nanoprecipitation process used for self-
assembly. Assembling structures from a much larger series of copolymers with varying PTMC 
block sizes may yield additional unexpected morphologies and give insight into how PTMC can 
be used for more controlled production of particle morphology. Indeed, apart from the vesicle 
morphologies all other structures produced were not expected and retroactive analysis of their 
structure was performed. These structures were not predicted or targeted. A larger study, 
involving a range of copolymers with carefully controlled molecular weights could help to 
understand the possible morphologies that can be produced from PTMC containing copolymers. 
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In this way, structure morphology can be more carefully controlled, and specific structural 
morphologies can be targeted.  
 As well, variations on the experimental protocol for nanoprecipitation can be altered to 
play on the morphology of specific copolymers. In doing this, the degree of crystallinity within 
the nanostructure could potentially be increased or decreased and maybe further give rise to 
additional particle morphologies. Self-assembly of semi-crystalline conjugates above the chain-
melting temperature may also give more predictable particle morphologies as the major 
influencing factor (chain crystallization) is not present. 
 
Temperature-tunable morphology in nanostructures 
As discussed in the literature review of this report, temperature has been used as an 
indirect inducer of morphology changes in structures containing semi-crystalline copolymers. 
These morphology changes were directly linked to the chain-transition temperature exhibited in 
structures with a crystalline nature. The structures produced in this work all exhibit this same 
transition, however, only the triblock systems was investigated in depth. Given the range of 
morphologies observed from the diblock copolymers produced, I would recommend that the 
effect of temperature and the chain-melting temperature be investigated. Work by Li et al has 
shown a compound micelle to core-shell transition in PEO-b-PE compound micelles upon 
heating above the Tm. Similar morphological changes may be observed with the range of 
structures produced in this work. Moreover, a thorough study on these structures could lead to 
particles with temperature-tunable morphologies, in which a specific structural architecture can 
be targeted by temperature adjustments.  
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In the same way that triblock systems were produced in this work, other triblock systems 
consisting of multiple crystalline blocks, with differing chain-melting temperatures, could give 
rise to structures with inducible, step-wise morphology changes. In the recommendations 
discussed, the goal should be to gain more control over the particle morphology so that 
nanoparticles can be produced in a more targeted and predictable way. 
 
Diblock and triblock hybrids as drug delivery systems 
One of the primary goals of this work was to produce vesicle structures capable of 
responsive and controlled drug release. This goal was achieved, and enhanced drug release was 
shown under changing temperature and pH conditions and importantly in the presence of the 
tumor-associated enzyme MMP-2. This triblock system holds potential to be further developed 
into a drug delivery system by pairing it with drugs particularly relevant to cancer therapy. 
Additionally, given the vesicle nature of the structure it is possible to load both hydrophilic and 
hydrophobic drugs into the carrier. This is one of the main advantages of the vesicle 
morphology, but has not yet been explored in this work. With multiple payloads loaded (in the 
membrane core and in the aqueous cavity), the release of each could be carefully controlled 
independently and in response to different stimuli (pH to release drugs from the aqueous cavity 
and temperature to release drugs from the membrane for example.). 
While the triblock system developed showed multi-responsive character, the vesicles 
produced from the diblock conjugates may also hold potential for further development. These 
structures showed significantly faster degradation in the presence of MMP-2 compared to the 
analogous triblock vesicles. This more rapid cleavage would likely result in a more prominent 
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enhancement of drug release compared to what was observed in the triblock vesicles. I would 
recommend that the PTMC13-b-PVGLIG vesicles be further investigated for controlled and 
induced drug release in the presence of MMP-2.  
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